O

n Friday, EACTS President Ruggero De Paulis stepped up to the podium to give his presidential address to a packed auditorium. After being welcomed on stage by EACTS Secretary General Domenico Pagano and Giacomo Genec, Professor De Paulis began by relaying his honour and pleasure to have served as President of the Association for the past year. “In moments like this I have a duty to thank all those who, in different ways, have worked closely with me and have contributed directly or indirectly to this achievement,” he said.

He began with an air of gratitude to the Past-Presidents of EACTS, before thanking Pieter Kappetein and Domenico Pagano for their hard work and guidance as Secretary Generals of EACTS. He then paid tribute to leading figures throughout his professional career, including Mario Morea and Jimmy Ottino from Turin, mentors during his residency, and Willem Kolff at the University of Utah. “Perhaps some of you won’t be aware, but Dr Kolff is a father of renal dialysis, the intra-aortic balloon pump, the artificial heart and many other achievements that are stamped in the history of modern medicine,” said Professor De Paulis. “He was always pushing us to think outside the box. Both he and his legacy are impossible to forget.”

From his experience in France, Professor De Paulis thanked Philippe Délouze and Gerard Block, who helped shape his case experience in the early days of his career. And to Rome, he honoured his former chief Luigi Chiarello for his lessons in perseverance and hard work in the face of challenging situations, as he did his current colleagues at the European Hospital. “It is because of them that I am here in front of you today,” he said. Finally, he thanked his family for their unending support.

Turning to EACTS, Professor De Paulis commented: “The passion for our work binds us together and makes it possible for an Association like this to continually grow, flourish and be cemented and nourished by our diversity – a diversity that resides in our cultures and in our stories, and in how we observe and solve problems. Different environments and professional formations are our strength, not our weakness, and underpin our ability to innovate and improve.”

“The Profession

“Today we are a great Association made up of a group of people who have a lot in common – much more than it seems at first sight. Even in an era of increasing inequality, we can all still share in the importance of health systems that offer free access to all citizens, giving them the right to the best available treatment. “We are a group of surgeons selected on the basis of certain key characteristics. First, we have the ability to endure a long and demanding course of training. Second, we can tolerate long and heavy hours of work, and we can endure bitter defeats – lessons that often touch us deeply, and yet give us the ability to analyse, metabolise and overcome failures to regain our spirit and strength the very next day. Furthermore, and very importantly, we have the ability to tread that thin line between the life of the patient and our abilities to complete our task.”

Continuing a legacy

How many times did the pioneers and founders of our profession experiment with new tools? What were the ethics that guided them? What is the right state of mind to adopt when testing a new instrument or idea? These were just some of the questions Professor De Paulis posed as he looked back on the work of visionaries of the past who helped shaped what cardiothoracic surgery is today. As he stressed, the journey from surgery’s humble beginnings at the hands of barbers to where it is now has required incredible effort, challenge and sacrifice – not least for patients – as medical professionals have striven to innovate and improve techniques, technologies and training.

With this in mind, Professor De Paulis went on to take a journey through three components of cardiothoracic surgery – the profession, innovation and ethics – with an overarching message that future practices in cardiothoracic surgery must be open and transparent.

“We must live in a house of glass”

“...we need to keep in mind that the profession has always been given a role of complete autonomy,” said Professor De Paulis. Within society, the role of the doctor is one that only those with medical training could make proper judgements, especially in the face of scientific and technological advances, and the patient was thus considered not competent enough to understand or participate in the medical decisions that lay ahead.

Then again, he continued, patients did not question the work of the doctor either, and this separation of ‘them and us’ was at least rooted in good intentions. “Over the years, improvement of knowledge and an increased general awareness has seen this paternalism replaced with patient autonomy and the sharing of therapeutic choices,” said Professor De Paulis.

He added: “When situations are complex, when the patient’s condition is severe, or when the risk of surgery is high, the special relationship between surgeon and patient is never more important. Patients are completely relying on their surgeon, thus are best comforted when the surgeon’s capacity, trustworthiness and integrity are clear to see.”

Unfortunately, however, over the
‘We must live in a house of glass’

Continued from page 1
years the medical profession has been accused of having somehow abused this privilege, with outside influences creeping in to dictate regulation, and in some cases investigate possible misconduct. In “these kinds of circumstances, our Association has an opportunity to remodel dialogue with society, to step outside the operating room and invest in a clearer, honest, and bright relationship,” he said. “In the house of glass where we are all called to enter, there is no room for omissions or secrets.”

Innovation
Innovation has an increasingly important role and wellbeing, continued Professor De Paulis. The more disruptive or ground-breaking the innovation, the faster it appears to be welcomed into practice, he added. “Just think of smartphone technology or TAVI, for example.” As he went on, innovation often derives from a careful and constant observation of the world around us. This was definitely true of this year’s honoured polymath, Leonardo da Vinci, whose genius – just like the pioneers of surgery – relied on the ability to ask questions, observe things and think about whether to go ahead in the direction of what he perceived as a personal but potentially more risky scientific interest, or to follow the traditional path that seemed safer for the patient but one which would have involved the replacement of the valve with a mechanical prosthesis. In the end, and not without a great internal torment, I overcame my fears and followed the instinct that told me that, if there were no problems, it would be the most favourable choice for the patient. I am delighted to say that things went well and, 10 years later, the valve continues to work well and the patient leads a normal life.”

At its core, Professor De Paulis’ massage was that surgeons face life-and-death decisions in everyday practice, and must be prepared to carry the weight and responsibility for them if advancements are to be made. While the rules of ethics tell us that the primary interest should be the wellbeing of the patient, innovation inevitably has to include secondary interests in order to thrive. These include the role of industry – after all, industry is instrumental in driving new generations of devices and technologies, and their relationship with doctors continues to be important in order to make sure innovation benefits from, and is nourished by, mutual competencies. Nevertheless, industry needs to generate business, and at some stage this is how the good relationship between doctors and industry was somehow infiltrated by suspicion, noted Professor De Paulis. “It is perceived that there are intentions existing beyond the primary interest of the patient, society loses confidence in medicine, and the result is constant pressure to control the economic relationship between doctors and companies from the outside.”

For instance, support of research by industry has been a great boon wherever academic finances are limited, but it is rare that industry sponsors studies that do not feature their drugs or products. As such, there are ethical dilemmas in pursuing this kind of research in a wider manner. “But the reverse is also true,” continued Professor De Paulis. “Too strict a regulation of these relationships can interrupt vital collaborations that were based on solid ethical ground. What is the solution? To wary again is the so-called house of glass. Relationships between industry and medicine should be transparent, free to enter, and with no shady corners.”

Professor De Paulis added that, in this context, EACTS could play a supporting and guiding role in the future, particularly in terms of helping individuals to learn how to analyse studies with a critical eye and, when the data influences our daily practice, how not to dwell on superficial readings. “We must be proficient in the study methodologies, in the statistical analyses and in the critical analysis of results,” he said. The Association could also have an important role in conflicts of interest, he said: “What we need to improve is the manner in which we effectively manage our conflicts of interest. Managing them in a prospective way avoids restrictive practices, which can undermine the relationship between industry and cardiac surgery. If indeed there are no conclusive data to show that patients can suffer damage from conflict of interest, from studies sponsored by industry or from greater incidence of misconduct, it is also true that we must all costs avert public perception of unorthodox practice in the medical-industrial relationship. If again, we must live in a house of glass.”

Final word
In his closing remarks, Professor De Paulis took a step back to emphasise that innovation is all well and good, but the biggest progress in cardiological surgery might still have to come from addressing the huge healthcare discrepancies seen throughout the world. “In the last few years I have had the good fortune of being involved in a commendable initiative of the Cape Town Declaration which has clearly demonstrated the need for improved access to cardiological surgery in countries where rheumatism is endemic,” said Professor De Paulis. “Today we have talked about innovation, defining it as having impactful change, but in this case it simply shows that the use of existing standard-of-care procedures would have a profound impact. And, if it immediately improves the conditions of millions of people, it certainly can be defined as progress. “We are Europe: it is our duty to call out inequality in health systems and eradicate injustice.”

Ruggiero De Paulis

Congratulations to Jaime-Jürgen Eulert-Grehn and Mir Timo Nazari-Shafti from Berlin for winning this year’s Jeopardy final! The team will now take on the North American champions for the overall title at the Society of Thoracic Surgeons meeting, 25–28 January in New Orleans, USA.
Next generation Perfusion Technology

Powerful beyond compare.

Capiox® NX19
Oxygenator with UltraPrime™ Technology

CDI® System 550, the next generation of Blood Parameter Monitoring

Our smallest, most advanced full-size adult oxygenator to date with UltraPrime™ Technology.

Visit Hall 2, Booth # 226 to learn more about our Perfusion Technology.
**Abstract | Cardio | SAVR - long term results, emphasis on particular sub-groups**

Kevin S. Kim¹,², Emilie P. Kelley-Côté³,⁴, Saurabh Gupta²,⁵, Ali Alsagehir²,⁵, Ahmad Mahkoudi²,³, Graham McClure⁴, Arjun Pandey⁴, Brooke Newsome⁴, Sophie W. Gao¹, Matthias Bossard¹, Tetsuya Isayama, Yushinshu Ikuta¹, Mike Walsh¹,⁶, Amit Gan⁷, Gordon H Guyatt²,³, Richard P. Whitlock²,⁴,⁵

Objective: To evaluate the long-term outcomes of mitral and tricuspid valve replacement in patients with end-stage renal disease (ESRD) who received mechanical or bioprosthetic valves.

Methods: We performed a systematic review and meta-analysis of outcomes of 24 observational studies (n = 9,421; 6,758 mechanical and 2,675 bioprosthetic) with a median follow-up of 3.5 years. Twenty studies were at high-risk of bias due to unadjusted confounding variables. We found no difference in 30-day mortality between bioprosthetic and mechanical valve recipients with dialysis dependent ESRD.

Results: At latest follow-up, mechanical valves were associated with a lower risk of mortality (RR 0.80, 95% CI [0.67, 0.97], p = 0.02, I² = 85%, very low quality evidence), but an increased risk of bleeding (RR 1.89, 95% CI [1.21, 2.96], p = 0.005, I² = 40%, very low quality evidence) and stroke (RR 1.62, 95% CI [1.15, 2.29], p = 0.006, I² = 0%, very low quality evidence). Valve-related complications did not differ significantly (RR 1.08, 95% CI [0.62, 1.88], p = 0.78, I² = 0%, very low quality evidence). Based on very low-quality evidence, mechanical valves in ESRD patients are associated with decreased risk of long-term mortality, but an increased risk of bleeding and stroke. No randomised studies inform the question. Most included studies did not address confounding or did not appropriately adjust for known confounding variables, preventing causal inference. Differences in outcome may be due to differences in baseline variables. Until higher quality evidence guides prosthesis choice in this population, physicians can discuss the results of this summary of evidence with patients to help guide the decision.

**References**


NEXUS™ Stent Graft System

Endovascular Aortic Arch Repair

- Two-modular stent graft design for endovascular aortic arch repair
- Off-the-shelf solution
- The only endovascular system approved for the repair of aneurysms and dissections
Closure of subpulmonary ventricular septal defect via right thoracotomy

Yasuhiro Kotani, Yosuke Kuroko, Naohiro Horio, Sachika Kadokawa, Yosusuki Kobayashi, Atsushi Tateishi, Shingo Kasahara
Cardiovascular Surgery, Okayama University Hospital, Japan

A minimally invasive approach by means of a right thoracotomy could be beneficial in terms of patients’ quality of life (QOL).

The purpose of this study is to see the surgical outcome of congenital heart surgery performed by right thoracotomies, and 2) to show a surgical video of subpulmonary ventricular septal defect closure (VSD) via right thoracotomy.

Retrostrophic study was performed in 1,162 patients who underwent simple congenital heart surgery from 1991 to 2016. Of these patients, 101 (8.7%) patients had a right thoracotomy approach. Diagnosis included atrial septal defect in 90 patients, VSD in 8 patients, partial atrioventricular septal defect in 1 patient, mitral regurgitation in 1 patient, and cor triatrium in 1 patient.

Our operative technique is as follows: 1. Vertical right sub axillary skin incision; 2. Enter through the 3rd or 4th intercostal space; 3. Use of the wound retractor to protect the skin; 4. Perfusion and drainage from chest (central cannulation). Consider femoral cannulation if patients weighing more than 30kg; 5. A catheter is placed at intercostal space 8th for operation of administration of pain medication.

There were no deaths, nor were there any cardiopulmonary bypass (CPB) related complications. No patients required conversion to median sternotomy, and there were no blood transfusions required associated with the thoracotomy.

We present a case of four-year-old, girl with subpulmonary VSD. Briefly, the chest was entered via right 4th intercostal space (Figure 1). After establishment of CPB, the ascending aorta was cross-clamped, followed by administration of cardioplegia. The aortic arch was opened at 1cm above the ST junction. The VSD was confirmed just below the right coronary cusp (Figure 2) and then closed with two pairs of 5-0 sutures. Figure 3 shows the wound which is hidden under the arm. Technical tips and pitfalls will be shown in the presentation.

In conclusion, minimally invasive approach is now proposed as the first choice of surgery in most of simple congenital heart defects. Our result showed that right thoracotomy approach can be performed without having a longer myocardial ischemic time compared to median sternotomy. Extended anatomic indication, such as subpulmonary VSD should be considered, if surgery can be performed without any complications.

Aortic dissection in pregnant women with Marfan syndrome: Clinical experience in 30 patients over two decades

Jun-Ming Zhu, Wei-Guo Ma, Yu Chen, Zhi-Yu Giao, Yi-Peng Ge, Cheng-Nan Li, Jun Zheng, Yong-Min Liu, Li-Zhong Sun
Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Despite its rarity, aortic dissection (AoD) in pregnancy is currently the third most frequent cause of maternal cardiovascular death, with Marfan syndrome (MFS) being the leading cause. The optimal management strategy for this rare but highly lethal catastrophe remains controversial due to the limited clinical experience. The report of Dr Zhu and associates from Beijing Anzhen Hospital represents personal clinical experience with, and offers valuable insights into, the optimal management of AoD in pregnant MFS women.

Between 1998 and 2019, the authors managed 30 pregnant MFS women sustaining AoD (27±10.7% in the first trimester or postpartum). Mean diameter of aortic sinuses was 59.6±17.5 mm and aortic size was <45 mm in 12.5% of TAADs (5/40) and in 83.3% of TBADs (5/6), respectively.

Except for one patient treated medically who tragically died with her fetus, 23 patients with TAAD were managed surgically. Strategies included caesarean delivery at 35.4±6.1 GWs, followed by aortic repair (at median delay 29 days) in 7 (29.2%); aortic repair at 18.0±5.8 GWs, followed by delivery (median delay 20 days) in 6 (25%); and single-stage caesarean delivery and surgery in 10 (41.7%) at mean 32.0±5.0 GWs. The respective maternal and fetal mortality rates were 28.6% (2/7) and 14.3% (1/7), 16.7% (1/6) and 66.7% (9/13), and 10.0% (1/10) and 20.0% (2/10), respectively. Of patients with TBADs, 5 was managed with delivery first (83.3%) followed by surgical repair in 2 and medical therapy in 3; respective mortality rates were 50% (1/2) and 100% (2/2) with surgery, 33.3% (1/3) and 33.3% (1/3) with medical therapy. Aortic repair was performed first in 1 patient with TBAD, followed by C-section, which resulted in maternal survival and foetal death. Follow-up was available in 96.7% (range 0.1–9.3) for mean 3.0±2.9 years. Survival were 75.4%, 69.6% and 62.6% at 1, 3 and 6 years for mothers, and 52.5% up to 6 years for children, respectively.

Their management decision is based on the types of AoD (surgical versus medical treatment) and gestational age (delivery or aortic repair first). For TAADs before 28 GWs, urgent surgery with close fetal monitoring (or, sometimes, abortion) is recommended. For TAADs after 28 GWs, urgent caesarean section is performed, followed by aortic repair. For TBADs, the approach is delivery first, followed by surgery or medical therapy.

During the past two decades, their treatment algorithm has evolved towards the goal of saving two lives, even for pregnancies before 28 GWs. Specific intraoperative strategies include using HTK solution and normothermia or mild hypothermia, minimising the duration of cardiopulmonary bypass (CPB), avoiding circulatory arrest before 28 GWs, and maintaining high flow rate (≥2.4 L/min per minute) and mean arterial pressures (≥70 mm Hg). To save a fetus before 28 GWs, meticulous maintenance of haemostasis (by avoiding hypoglycaemia and hypomagnesaemia) and aggressive monitoring of fetus heart and movement are emphasised; and the HTK solution is aspirated away immediately away to prevent it from entering systemic circulation, minimising the impact of CPB on the fetus. The favourable outcomes in this cohort have proved the efficacy of the treatment algorithm of the Anzhen group, which is helpful to all physicians engaged in the care of pregnant women with MFS sustaining aortic dissection.
Five-year data on the RESILIA tissue valve in the aortic position did not show any structural valve deterioration (SVD), promoting to shift the paradigm in aortic valve replacement (AVR) towards the use of bioprostheses in ever younger patients as well as offering more patient choice.

Yesterday’s Edwards Lifesciences-sponsored symposium had a record turnout with nearly 400 attendees, all keen to hear the latest data on Edwards Lifesciences’ valves. Experts presented the 5-year durability data of RESILIA tissue; a critical review of the safety and performance of various valves including INSPIRIS; advice on making the guidelines more pragmatic, and real-world issues. Speakers were Krzysztof Bartolus (Poland), Sunil Ohri (UK), Christopher Young (UK) and Thierry Bourguignon (France) respectively.

Cardiac surgeon, Sunil Ohri (University of Southampton NHS Foundation Trust, Southampton, UK) took the audience through his experience of his group in Southampton with a five-year follow up on 1000 implanted bioprosthetic valves of various brands. Based on these data, he said, “the INSPIRIS may be a game-changer because if you have a valve with no SVD at five years, then our whole approach to how we inform our patients about long term outcomes with bioprosthetic valves will change,” Professor Ohri asserted.

“Of our patients, 892 received isolated AVR, and our mortality for that was 0.45% which is one of the lowest mortality rates for isolated AVR,” emphasised the surgeon and researcher.

“With the Edwards’ valves – the PERIMOUNT or Magna Ease, we had 0% re-intervention rate,” he highlighted. Also, the INSPIRIS valve is TAVI-ready meaning a balloon can be inserted into the valve and it clicks open, said Professor Ohri, noting a distinct benefit with INSPIRIS.

Professor Ohri identified that there was a grey zone in choosing a bioprosthetic or mechanical valve with patients aged 60–65 years, with European guidelines noting that placing a bioprosthetic valve into a 60 year old was reasonable if the patient agreed, but that a mechanical valve should be considered in someone under 60 years, if the patient agreed.1 “The US guidelines say a mechanical valve is reasonable if the patient is less than 60 years with no contraindications to anticoagulant therapy.”

However, he insisted that in 2019, the priority should be informed patient choice. “We provide the latest information from the literature and then the patient makes up their own mind based largely on their lifestyle choice.”

Professor Ohri asserted: “Patients under 60 years, who want to avoid lifelong medication might still want a bioprostheses and in this case then the INSPIRIS would be my first choice. I am persuaded by both the animal data on INSPIRIS, and the reduction in calcification, as well as the evidence coming through in terms of clinical experience. The ability of the INSPIRIS valve to fracture and the area bigger to bigger to TAVI (transcatheter aortic valve implantation) valve is a huge advantage for patients that may return requiring TAVI intervention.”

Valves with novel RESILIA tissue

Professor Bartus presented results of the 5-year outcomes of an AVR study using bioprosthetic valves constructed from novel RESILIA tissue. The case were all treated in Institute of Cardiology in Warsaw and at John Paul II Hospital, Krakow, where the professor and his colleagues have a long history of clinical trial work. The study represents the longest-running evaluation of bioprostheses with RESILIA tissue. “We are very encouraged by the clinical outcomes,” he remarked at the lunch symposium. “Through the five follow-up of study, the study showed favorable and excellent orifice areas [EOAs]. We also saw an excellent safety profile, including no cases of SVD.”

RESILIA tissue is bovine pericardial tissue transformed by a novel integrity preservation technology that permanently blocks and eliminates exposure to free aldehydes (due to the technology involving tissue preservation with glycerol), which are a major source of tissue calcification. Moreover, this technology also allows the valve to be stored under dry packaging conditions avoiding the need to rinse it prior to implantation.

The prospective, single-arm, observational clinical trial lead by Professor Bartus aimed to confirm the safety and performance of novel bioprosthetic valves made using RESILIA tissue. A total of 133 adult patients diagnosed with aortic valve disease requiring AVR were enrolled. Some participants underwent concomitant procedures such as coronary artery bypass grafting (CABG), but all were due to be implanted with the Edwards Lifesciences Pericardial Aortic Bioprosthesis, Model 11000.

Patients were followed for six months and annually up to five years. Multiple safety and effectiveness endpoints were assessed in the study including haemodynamically (orifice area and mean gradient); safety (adjudicated by an independent Clinical Events Committee) and procedural outcomes.

Regarding the results, Professor Bartus reported that all 133 patients were implanted with the test valve in the first attempt with 100% technical success, while 86% received isolated AVR, 44% were valve size 19–21 mm, and 88% received a full sternotomy. Haemodynamic performance was good at five years with a low mean gradient (baseline 49.4 mmHg compared to 14.8 mmHg at five years), and an acceptable orifice area (with 44% of valves being 19 and 21 mm), and no major paravalvular leaks at five years. Also, the New York Heart Association (NYHA) Class positively changed over the five years with 100% class III improving, and 51% of class II improving.

“We found that RESILIA tissue, which is now mounted on the INSPIRIS valve, brings a very low rate of complications, as well as having a very good safety profile,” highlighted Professor Bartus.

“The technology eliminates further degeneration in the tissue and it should last much longer meaning that any re-intervention will be delayed.”

This durability benefit facilitates the use of longer-lasting valves in younger patients, as opposed to mechanical valves, noted the professor. “Patients don’t need anti-coagulants and the associated complications of bleeding and thrombotic events common with mechanical valves, so the quality of life for younger patients could be so much better with a bioprosthetic valve.”

Professor Bartus explained how bioprosthetic valves, in particular INSPIRIS with RESILIA tissue, were changing practice. “Previously, in our practice, about 80% of patients received a mechanical valve but over the last ten years, this has changed significantly,” he remarked. He said the information is partially explained by the fact that patients are living longer and wish to have a good quality of life. “This RESILIA tissue technology might extend the longevity of this generation of valve.”

Mr Young (Guy’s and St. Thomas’s NHS Foundation Trust, London, UK) discussed the current guidelines and their role in determining which valves should be used in different patients. “Guidelines are perceived as almost being written on tablets of stone, but in my view, guidelines are there to help, yet they are treated like the law and people are thinking outside of the box less and less, to the detriment of the patient.”

Regarding guidelines around when to use a mechanical valve versus a bioprosthetic valve, Mr Young asserted that he totally disagrees with them. “European guidelines say mechanical up to 60 years and tissue up to 70 years, and in between, we argue about it. In reality, patients want tissue valves not mechanical, so in our practice, we put tissue valves in 30 and 40-year olds.”

Finally, Dr Bourguignon (Tours University Hospital, Tours, France) took to the podium to discuss real-world evidence for the use of RESILIA tissue, starting the four-year follow-up of the PrimoCative, nOn-randoMized, MultiCenter Clinical Evaluation of Edwards Pericardial Aortic Bioprostheses. With a New Tissue Treatment Platform (COMMANDe) trial. This trial is a prospective, open-label, multi-centre study of RESILIA tissue mounted in a Magna Ease bioprosthetic valve. With a fow-up, the present data on around 800 people.

“There were no cases of endocarditis in the last analysis, and secondly, the haemodynamics are very satisfying especially in the PERIMOUNT valve. Together, these results are very promising,” he said.

He also briefly discussed real-world experience with use of INSPIRIS valve for most of Europe and for France. “In Tours University Hospital we have implanted over 250 patients with the INSPIRIS valve since June 2017 and confirm excellent short-term outcomes.”

The novel design of the INSPIRIS RESILIA aortic valve has recently been recognised with a nomination for the prestigious 2019 Annual Prix Galen prize from the US Galen Foundation. Of note, the design leverages features of the trusted Carpenter-Edwards PERIMOUNT aortic valve and is built on the proven performance of the Carpenter-Edwards PERIMOUNT valve including being mathematically modelled and bioengineered with three independent leaflets matched for thickness and elasticity mounted on a flexible, radiopaque cobalt chromium alloy wireframe.

Expert opinion, advice and all other information expressed represent contributors’ views and not necessarily those of Edwards Lifesciences.

References
Tricuspid valve repair in children with hypoplastic left heart syndrome: Impact of timing and mechanism on outcome

Introduction

Tricuspid regurgitation (TR) in children with hypoplastic left heart syndrome (HLHS) remains a significant risk for successful staged palliation. Significant TR may emerge at various points; at birth, after the Norwood procedure, after volume unloading by stage II palliation, and before or at the Fontan procedure. Previous studies have shown that mechanisms of TR in HLHS are complex and multifactorial, that changes in TR in HLHS are complex and that mechanisms of TR at the initial repair were enumerated based on operative records. Risk factors for death, redo operation and TV replacement following the initial repair were identified using Cox regression models.

Objectives

Our aim was to evaluate the results of TV repair in patients with HLHS during staged reconstruction focusing on the timing of the repair and the mechanisms of TR, and to analyse risk factors influencing survival, redo operation, and TV replacement.

Materials and Methods

We reviewed the medical records of 249 consecutive patients with classic HLHS who underwent a Norwood procedure at the German Heart Center Munich between 1999 and 2018, and 44 patients (18%) who underwent TV repair during staged reconstruction were included in this study. Mechanisms of TR at the initial repair were enumerated based on operative records. Risk factors for death, redo operation and TV replacement following the initial repair were identified using Cox regression models.

Results

TV repair was performed before stage II (BCPS) in 4 patients (9.1%), concomitant with stage II (BCPS) in 23 (52.3%), between stage II and stage III (Fontan) in 3 (6.8%), and concomitant with Fontan in 14 (31.8%). The median age at initial TV repair was 5 (3 to 19) months. Preoperatively, 27 patients (61%) had moderate TR and 17 (39%) had severe TR.

Methods of TR at the initial repair were identified as a risk factor for mortality (p = 0.013) and TV replacement (p = 0.015). Lower weight at the initial TV surgery (HR: 0.77, p = 0.014) and lower TAPSE pre Norwood (HR: 0.73, p = 0.015) were independent risk factors for mortality and TV replacement, respectively. The most common surgical techniques were approximation (HR: 5.5, p = 0.042). Among morphological variables, restrictive septal leaflet anomalies, is mandatory to improve outcomes.

Mechanisms of tricuspid regurgitation

Most commonly, TR emanated from the annulo-saital (AS) commissure (n = 21, 43%), anterior leaflet prolapse was identified in 23 (52%) and posed the most common pathologic TR (Table 1 and Figure 1). Among morphological variables, restrictive septal leaflet anomalies were identified as a risk (HR: 3.6, p = 0.042). In multivariate analysis, TV surgery before stage II (HR: 5.5, p = 0.042) and lower weight at TV surgery (HR: 0.77, p = 0.015) were significant risk factors for reoperation. Anterior and posterior leaflet chordal anomalies were significantly associated with a higher risk for TV reoperation (HR: 4.4, p = 0.037 and HR: 7.4, p = 0.015) on univariate analysis, and pre-stage II operation was a significant risk on multivariate analysis (HR: 5.9, p = 0.013).

Conclusions

TV repair is most commonly performed as a concomitant procedure during stage II palliation. Most often TR emanates from the AS commissure. Anterior leaflet prolapse and restriction of the septal leaflet are the main mechanisms of TR. Early recognition of significant TR before stage II palliation was a significant risk for worse outcome. Among morphological variables, restrictive septal leaflet anomalies was a risk factor for TV replacement. Development of a refined repair approach, especially for septal leaflet restriction and chordal anomalies, is mandatory to improve outcomes.

References


INSIDE LISBON
Where to go? What to do?

ROOFTOP VIEWS

SKY BAR
Sitting atop the Tivoli Avenida da Liberdade Hotel, this stunning venue has one of the best views over the city. Cocktails and mocktails abound, and there’s light menu if you’re feeling peckish.

BAR PARK
A conversion of the top floor of a multi-storey car park, Bar Park doesn’t sound that appealing on paper, but in reality it’s a hidden gem. With potted trees and plants, it’s a veritable garden paradise with a front seat at Lisbon’s gorgeous vista.

SILK
A 360° panorama awaits you at this swanky, upmarket bar/Japanese-restaurant in the Chiado district. Joining you will be the resident DJ who takes the party late into the night.

OFF THE BEATEN TRACK

AJUDA
Just a few kilometres Northwest of the Centro de Congressos is Ajuda, one of Lisbon’s oldest neighbourhoods. It’s a lot quieter than the main tourist areas, and has some absolutely beautiful sights, including the Jardim Botânico da Ajuda (Portugal’s oldest botanical garden), the Palácio Nacional da Ajuda (neoclassical architecture with a museum) and the more than 100-hectare Tapada da Ajuda parkland.

LIVRARIA BERTRAND
Opened in 1732, Livraria Bertrand is the oldest running bookshop in the world. It’s open every day, so pop in, curl up on one of its cozy sofas and dust off a centuries-old classic.

FAMOUS FLEA MARKET
The 13th century Feira da Ladra (‘thieves market’) is a must-do if you are staying a little longer in Lisbon. Open Saturdays and Tuesdays, you can be sure to pick up wonderful and weird bargains to take home.
Five-year outcomes of surgical left atrial appendage amputation on stroke prevention in patients undergoing off-pump coronary artery bypass grafting

**Daisuke Endo, Taira Yamamoto, Satoshi Matsuishi, Kan Kajimoto, Akie Oishi, Tohru Asai, Atsumi Oishi, Daisuke Endo, Taira Yamamoto, Satoshi Matsushita,**
**Juntendo University Hospital, Tokyo, Japan**

**S**

Stroke is a major adverse event in patients developing atrial fibrillation (AF) after cardiac surgery. In nonvalvular AF, 90% of left atrial thrombus occurs in the left atrial appendage (LAA). Anticoagulation is a well-established treatment, but issues such as device-related thrombus and peri-device leak. Among the several procedures available for surgical LAA closure, LAA amputation (LAAA) is the most reliable technique. The endocardium where the LAA is located is very smooth without a remnant (Figure 3). We report five-year outcomes of surgical LAAA in patients undergoing off-pump coronary artery bypass grafting (OPCAB) to confirm findings and short-term results. This is the first demonstration of the effectiveness of prophylactic surgical LAA in patients with preoperative sinus rhythm in whom 30% develop AF after OPCAB. We analysed 1,018 consecutive patients (mean age 67 years, male 82%) undergoing OPCAB with or without concomitant LAAA from 2011 to 2017 at our institution in a prospective, observational manner. The safety and efficacy of the concomitant LAAA on preventing early (< 30 days) and overall postoperative stroke were examined. A total of 574 patients (56.4%) underwent LAAA. Preoperative characteristics, operative time, requirement of blood transfusion, and 30-day mortality were not significantly different between those with and without LAAA. The incidences of postoperative AF and early stroke were not significantly different between the groups. The incidence of overall stroke was higher in patients without LAAA than those with LAAA (4.5% vs 1.7%; p = 0.01). In a subanalysis of patients without LAAA, early and overall stroke occurred more frequently in those developing postoperative AF than those without AF (3.0% vs 0.0%; p = 0.02; 9.0% vs 2.6%; p = 0.004, respectively), while in patients receiving LAAA, stroke incidences did not differ between those with and without AF. Multivariate cox proportional hazard models showed postoperative AF (Model 1) and postoperative AF without LAAA (Model 2) as the only independent positive predictor of overall stroke, respectively (OR 2.21, p = 0.03 and OR 3.11, p = 0.003). Model 1 used postoperative AF as a solitary covariable and model 2 used a combination of postoperative AF and LAAA as a covariable. Postoperative AF was the independent risk factor of stroke. Concomitant LAAA as a routine procedure in OPCAB is beneficial.

**References**


**Figures**

1. In our approach, a 4-0 polypropylene purse-string suture was placed on the neck of the left atrial appendage (LAA) (Figure 1), and resected. A double-running suture was used to close the stump of the LAA (Figure 2), which was at low cost with no device used.

2. The endocardial scar after the surgical left atrial appendage amputation (LAAA) was smooth with no remnants.

Academy

STS/EACTS Latin America Cardiovascular Surgery Conference
22–24 November 2019, Cancun, Mexico
José L Pomar Hospital Clinic and University of Barcelona, Spain; on behalf of the Programme Directors

EACTS, together with the Society for Thoracic Surgeons (STS) and our colleagues from Latin America are delighted to announce the third annual STS/EACTS Latin America Cardiovascular Surgery Conference, taking place in Cancun, Mexico this November. Attendees can expect an outstanding educational programme spanning coronary artery disease, valvular heart disease, thoracic aortic disease, atrial fibrillation, the surgical management of heart failure and additional tracks covering congenital heart disease, research, databases, leadership and fellowships.

The conference is for young surgeons, residents and fellows from all over the world, with particularly strong links to Latin America. Cardiothoracic and cardiovascular surgeons, cardiologists, anaesthesiologists, perfusionists, physician assistants, nurses and other interested healthcare professionals are all more than welcome to attend.

Because we understand that skills are obtained not only by observing step-by-step techniques performed by masters in the field, this year we have organised wet labs and simulator training sessions led by some of the most prominent European and American specialists. These sessions will span topics including mitral, tricuspid and aortic valve operations as well as procedures of the aorta.

Throughout the proceedings we will feature smaller-format, intimate sessions (e.g. more highly scientific lectures, abstract presentations and state-of-the-art keynote lectures will be showcased. Simultaneous translation will be offered during all lectures and a selected faculty will also provide the necessary translation during the hands-on sessions.

As in past years, Course Directors Joseph Bavaria and Vinod Thourani (STS) and Juan Pablo Umaña and Nestor Sandalio (Colombia), Patrick Parer and myself from EACTS will head-up this important collaboration with current and elect presidents of the Mexican Society of Cardiac Surgery Alejandro Rey, José Antonio Henidea Delgado and Edgar Samuel Ramirez Moran, respectively.

The STS/EACTS Latin America Cardiovascular Surgery Conference is establishing itself as a very important event for our specialty around the world. Therefore, much care has been taken in selecting speakers, topics and moderators that will ensure the conference has the highest impact in the education of our young, up-and-coming colleagues.

We very much look forward to seeing you in Cancun in November!

Focus Session | Thoracic | Lung Failure (Transplantation, ECMO and pulmonary endarterectomy)

Bilateral lung transplant with cardiac repair vs combined heart-lung transplant in patients with Eisenmenger’s syndrome

Federico Sertic, Jason Han, Dieynaba Diagne, Thomas Richards, Lexy Chavez, Ashley Berg, Joyce Wald, Maria M Gregorio, Eduardo Ramos, Christian Bermudez Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Unrepaired congenital shunts such as ventricular septal defect (VSD) and atrial septal defect (ASD) are the most frequent causes of Eisenmenger’s Syndrome (ES). This condition is characterised by a reversal of flow in the shunt due to irreversible pulmonary hypertension leading to progressive symptoms. Heart-lung transplantation (HLT) and bilateral lung transplantation (BLT) with concomitant repair of the underlying cardiac defect have both been offered to patients with ES as effective curative therapies with 1-year survival ranging from 55-84% 1-5. However, the most effective surgical approach remains controversial and the procedure may be influenced by anatomical considerations and organ availability. Therefore, in this study we evaluated the outcomes of patients diagnosed with ES receiving HLT or BLT with repair of cardiac defects using a US national registry.

We queried the United Network for Organ Sharing (UNOS) registry for all adult patients with ES who underwent thoracic organ transplantation between 1987 and January 2018. We identified 316 patients who underwent HLT and 126 patients who underwent BLT with concomitant cardiac defect repair. These two groups were propensity-score matched by age, gender, BMI and type of cardiac defect.

The most common causes of ES undergoing transplantation were atrial septal defects (VSD) 44%, HLT 25%) and ventricular septal defects (ASD 33%, HLT 38%). Overall survival, including all types of cardiac defects (ASD, VSD, PDA, multiple congenital abnormalities and other), was similar between the two groups undergoing BLT and HLT (p = 0.2). In the propensity-matched analysis, looking at ASD patients, we demonstrated that BLT with defect repair was associated with a better 1-year survival (BLT 88.3% vs HLT 63.3%, p < 0.01; 3-year survival BLT 71.1% vs HLT 49.8%, p < 0.01), and 5-year survival (BLT 50.1% vs HLT 44.2%, p = 0.1). Figure 1. By contrast, matched patients with VSD have significantly better outcomes when treated with combined HLT 1-year survival BLT 49.6% vs HLT 78.2%, p = 0.01; 3-year survival BLT 41.2% vs HLT 63.3%, p = 0.01; 5-year survival BLT 34.3% vs HLT 55.6%, p = 0.01; Figure 1). As detection and management of pulmonary hypertension and congenital abnormalities have improved preventing the development of ES, few studies 2,5,7 have been able to study sizeable cohorts of adult patients with unrepaired congenital heart disease. While HLT was initially the procedure of choice for all patients with pulmonary hypertension, there is a paradigm shift towards considering double or even a single LT as an alternative given lesser waiting time, lower immunologic complications and most importantly improved resource allocation. In this study patients with ES secondary to ASD demonstrated superior outcomes after BLT alone, finding that not been clearly demonstrated previously in the limited literature available, suggesting that dual organ transplantation (HLT) may come with additional risks in this population. On the contrary, more complex abnormalities (including VSDs) leading to ES may benefit from HLT as found in this and other studies.

Although considered a higher risk population, thoracic organ transplant in ES remains a viable treatment option.

In patients with complex cardiac defects, including VSD, combined HLT has superior short and long-term outcomes compared to BLT with cardiac repair. In patients with simple cardiac defects, including ASD, BLT with concomitant cardiac defect repair should be considered as the first line treatment option given the organ shortage. This data may be useful when considering the major changes in organ allocation and their effect in the ES population.

Figure 1. Five-year survival in patients (HLT vs BL) matched by type of cardiac defect (ASD or VSD).

References

Hosted by STS/EACTS Latin America Cardiovascular Surgery Conference, November 2019

Federico Sertic (left) and Christian Bermudez

[Image of speakers at conference]
A direct correlation between commissural orientation and annular shape in aortic valves: a new anatomical and computed tomography classification

Philipp Angleitner1,2, Markus Tschegg1,2, Kairat Kurnosov1,2, Patrick Fischlein3,4, Jörn Fischbach5,6, Ralf Giese7,8, Tobias Amann9,2,9

Figure 1. The new anatomical and computed tomography classification of aortic valve types, correlating the commissural orientation with the annular shape.

Our study confirms the correlation between the commissural orientation and the annular shape of aortic valves.

The shape of the aortic annulus is of great importance. Recent findings suggest a possible gradual spectrum of circularity from tricuspid aortic valves (TAVs) to Type 1 bicuspid aortic valves (BAVs) to Type 0 BAVs. Commissural orientation (CO) in BAVs is often asymmetrical, classified according to the shape of the annulus.

In conclusion, this study confirms the expected linear correlation between the CO and the shape of the aortic annulus.

In particular, the aortic annulus follows a continuous spectrum of circularity depending on the CO, starting from a perfectly circular shape for a CO of 160°–180° to an elliptical shape for a CO of 120°–139°, passing through an intermediate state for a CO of 140°–159°. These findings lay the groundwork for a comprehensive new anatomical and geometric classification, while at the same time based on CO and annular shape.

References
Aortic valve-sparing root replacement was introduced for the treatment of aortic root aneurysms in the early 1990s. Valve-sparing operations yield a sound outcome, offering the benefit of preserving the patient’s native aortic valve and thereby avoiding prosthetic-associated complications. While the results are excellent in patients with bicuspid aortic valves, the long-term performance and durability of valve-sparing operations in patients with bicuspid aortic valves has been questioned and remains a subject of debate. The aim of this study was to analyse the short- and long-term outcomes in patients with bicuspid aortic valves over a time period of more than twenty years. We retrospectively analysed a total of 562 patients who underwent aortic valve-sparing root replacement using the original reimplantation technique (David I) at our centre. Among these patients, fifty had a bicuspid aortic valve. Bicuspid aortic valves were classified according to the Slevens classification, and we found that type 0 and type I were distributed equally. There was no periprosthetic leak and only one patient had a permanent neurological deficit. Therefore, we feel that it is appropriate to say that aortic valve-sparing root replacement is safe and has satisfactory short-term outcome.

We also conducted a follow-up which was complete for all patients. The mean follow-up time was eleven years – a relatively long timespan which is adequate to analyse and assess long-term outcomes. We compared the rate for freedom from aortic valve-related reoperation of bicuspid aortic valve patients to the reoperation rate of patients with a tricuspid aortic valve, seeing no significant difference. Therefore, we find that the long-term durability of a repaired bicuspid aortic valve is comparable to a preserved tricuspid aortic valve.

The benefit of preserving the bicuspid aortic valve has to be weighed against the risks and benefits of prosthetic graft replacement. While mechanical valve prostheses have the risk for thromboembolism, including stroke, biological valve prostheses deteriorate relatively quickly, especially in young patients. Previous studies (Chan and colleagues, Circulation, 2011) reported a 10-year rate for freedom from reoperation of 63% in middle-aged patients and 55% in patients aged 40 years or younger. This number is significantly lower than the rate of freedom from reoperation in our study, which is 82% percent. Therefore, we believe that aortic valve-sparing root replacement using David’s reimplantation procedure is a useful technique especially in young patients and those with a bicuspid aortic valve.

We also performed a multivariate logistic regression analysis to identify risk factors for aortic valve-related reoperation. The only variable was the risk factor for reoperation was commissure repair at the time of surgery. In our clinical practice, we have learned that this repair technique does not provide sufficient long-term durability, and therefore we have abandoned this technique.

The incidence of metachronous second primary lung cancer (MPLC) after curative resection of primary lung cancer has been increasing due to improved surgical outcomes and early detection and postoperative surveillance of lung cancer. Thanks to advancements in chest CT, MPLC can be identified at an early stage and treated with secondary pulmonary resection. However, surgical complications are increasing because of the decreased physical function of patients, as well as technical concerns – especially isoperistaltic MPLC, which requires redo-thoracotomy.

Stereotactic body radiotherapy (SBRT) has now widely been used in the treatment of early stage lung cancer, and produces equivalent outcomes to pulmonary resection. However, we believe that surgery is superior to SBRT for operable MPLC patients. Surgery can remove whole tumours (particularly relevant for large tumours), co-existing interstitial lung disease, and centrally located tumours that are not appropriate for SBRT. In this study, we aimed to compare outcomes of MPLC patients treated either with surgery or SBRT in Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

The study involved comparing outcomes of MPLC patients treated either with surgery or SBRT in Nagasaki University Hospital from 2008 to 2018. Propensity score matching (PSM) was performed to reduce bias in various non-homologous factors. The definition of MPLC was based on Martini and Milsom. Secondary surgery was performed in 51 cases, and SBRT in 26 cases. Patient characteristics (values/median) including gender (67/65%), age (73/77 years), time from first surgery (6/24.7 years), first surgical procedure (lobectomy, 82/85%), second tumour size (11/12 mm), clinical stage (stage I, 96%100%) and CEA (2.9/3.0 ng/ml) was not significant between treatment groups.

However, in the surgery group, ipsilateral secondary tumours (71/58%, p = 0.003) were significantly dominant. In addition, there was better performance status (p = 0.03), and preserved lung function (p = 0.02). Thus, surgery tended to be selected in patients of good physical function with contralateral MPLC. Before PSM, five-year overall survival (OS) after surgery (86.5%) was not significantly different compared to that of SBRT (86.5%), log-rank, p = 0.24. Nor was five-year cancer-specific survival (CSS) after surgery (85.9%) compared to that of SBRT (94.7%, log-rank, p = 0.55). Even after matching, the difference in five-year OS and CSS was insignificant between the matched pairs (100%, 84.4%, p = 0.73 and 92.9%, 92.3%, p = 0.192).

In conclusion, surgery and SBRT for MPLC patients is a safe and feasible treatment option, with outcomes similar to that of SBRT. However, the compared cohort in this study does include bias, despite the use of propensity score matching. Thus, a well-designed randomised controlled trial with a large sample size is now required.
Impact of brain protection strategies on mortality and stroke in patients undergoing aortic arch repair with hypothermic circulatory arrest: Evidence from the Canadian Thoracic Aortic Collaborative

Ali Hage1, Louis-Mathieu Stevens2, Maral Ouzounian3, Jennifer Chung3, Ismail El-Hamamsy4, Vincent Chauvette4, Francois Dagenais4, Andreanne Cartier5, Mark Peterson6, Munir Boodhwani7, Ming Guo8, John Bozinovski9, Jeevan Nagendran10, Abigail White11, Kanwal Kumar11, Carly Ledewitsky12, Bindu Bittira13, Darrin Payne14, Michael WA Chu15, on behalf of the Canadian Thoracic Aortic Collaborative.

1. Western University, London, ON, Canada; 2. University of Montreal, Montreal, QC, Canada; 3. University of Toronto, Toronto, ON, Canada; 4. Laval University, Quebec City, QC, Canada; 5. University of Ottawa, Ottawa, ON, Canada; 6. University of British Columbia, Victoria, BC, Canada; 7. University of Alberta, Edmonton, AB, Canada; 8. University of Manitoba, Winnipeg, MB, Canada; 9. Health Sciences North, Sudbury, ON, Canada; 10. Queen’s University, Kingston, ON, Canada.

Abstract

Objective: To do so, we looked at a total of 2,520 patients who underwent aortic arch repair with hypothermic circulatory arrest (HCA) between 2002 and 2018 in 11 centres of the Canadian Thoracic Aortic Collaborative. Our primary outcomes included mortality, stroke, a composite of mortality or stroke, and a newly defined composite outcome for mortality or major morbidity (STS-COMP) including stroke, reoperation, renal failure, prolonged ventilation, and deep sternal wound infection. We performed multivariable logistic regression and propensity score matching for cerebral perfusion and nadir temperature practices in order to identify independent predictors of outcomes.

Antegrade cerebral perfusion was found on multivariable analysis to be protective against mortality (OR 0.64, 95% CI 0.48–0.86, p = 0.003), stroke (OR 0.55, 95% CI 0.37–0.81, p = 0.006), composite of mortality or stroke (OR 0.57, 95% CI 0.45–0.72, p = 0.0001), and STS-COMP (OR 0.53, 95% CI 0.41–0.67, p < 0.0001), as compared to HCA alone. Retrograde cerebral perfusion yielded similar outcomes as compared to antegrade cerebral perfusion.

When compared to HCA with nadir temperature < 24°C, a propensity score analysis of 647 matched pairs identified nadir temperature ≥ 24°C as predictor of lower mortality (OR 0.62, 95% CI 0.40–0.98, p = 0.04), stroke (OR 0.51, 95% CI 0.31–0.84, p = 0.008), composite of mortality or stroke (OR 0.62, 95% CI 0.43–0.89, p = 0.021), and STS-COMP (OR 0.64, 95% CI 0.49–0.85, p = 0.002).

We conclude that antegrade cerebral perfusion and nadir temperature ≥ 24°C during HCA for aortic arch repair are independent predictors of improved survival and neurological outcomes.

Do we undertake too many blood tests after cardiac surgery?

Sobaran Sharma, Joseph George

Department of Cardiothoracic Surgery, Morriston Hospital, Swansea, UK

Post-operative cardiac surgical patients undergo intensive monitoring, including multiple serial blood testing for arterial blood gas monitoring and routine blood panels. There is increasing recognition of the total blood utilised to undertake these blood tests. Our aim in this study is to quantify the blood loss from routine blood testing. We also evaluate the haemoglobin concentration and transfusion requirements after cardiac surgery and its financial implications.

We discovered that patients undergo a significant amount of blood testing post-operatively in routine monitoring. In our series of more than 300 patients over six months, we examined the total number of blood tests, and the volume of blood used. An average of 77 samples were taken post-operatively, from admission to intensive care to discharge from the hospital. This equated to 415 ml of blood withdrawn from the patient. Blood gas samples, though only about 1 ml, requires an additional 5 ml to be withdrawn first to clear the line, i.e. 6 ml per analysis. Thus, 240 ml on average was utilised solely on blood gas samples. This represents more than 58% of the total volume withdrawn for testing.

In addition, patients were being transfused an average of 2.8 units of red cells, though a third of patients did not require any transfusion. However, this represents not only a substantial clinical cost to the patient but also a well-known adverse short and long-term effects of blood transfusion, but also a financial cost of £128,550 to the institution. Patients’ haemoglobin concentration dropped by an average of 27 g/L.

Blood used for phlebotomy, when represented in units of red cells, amounts to approximately 1.5 red cell units. Although we cannot conclude on causality between phlebotomy and post-operative anaemia, we can infer that blood drawn for tests may have a significant impact on the patient’s haemoglobin concentration resulting in anaemia and need for blood transfusion. We hope that any strategies or protocols for blood conservation in cardiac surgery will also scrutinise the significant impact of phlebotomy volumes. Our study is the first to report results from a European perspective and gives further insight into the potential areas where blood test volumes could be minimised.

Abstract | Cardiac | Improving outcomes by a perioperative personalized blood management

Do we undertake too many blood tests after cardiac surgery?
Double -root rotation: feasibility in model of structurally normal hearts

Patrick O Myers, Jean Henri Dominique Fasel, René Prêtre, Tornike Sologashvili
Lausanne University Hospitals and Geneva University Medical School, Switzerland

Abstract | Congenital | Congenital Valve

The Ross operation is the gold standard for management of the unreparable aortic valve in children and young adults. However, if reimplantation of a right ventricle to pulmonary artery (RV-PA) conduit, which subsequently requires reinterventions and reoperations. A procedure that would avoid these reinterventions, while offering the benefits of the pulmonary autograft in the aortic position, would therefore be desirable. In patients with transposition of the great arteries, ventricular septal defect (TGA-VSD), and pulmonary stenosis, double-root translocation or outflow-tract rotation has been used effectively to recycle the stenotic pulmonary valve, avoiding the RV-PA conduit necessary in a ‘repair stage ventriculare’ (REV) or Rastelli procedure. We hypothesised that a similar operation could be offered for congenital aortic stenosis, however the feasibility in a structurally normal (non-TGA-VSD) heart is unknown. Furthermore, in TGA-VSD, the ventricular septal defect pushes the conduction system further away from the sub-arterial plane, protecting it during the double-root rotation. The conduction system could be more at risk during the harvesting of these roots in a structurally normal heart than a TGA-VSD-PS heart. The aim of this study was to assess the feasibility of harvesting both roots in a structurally normal heart and to identify potential pitfalls. Two structurally normal human donor cadaveric hearts were dissected to assess the feasibility of double-root translocation, first in a formaldehyde-fixed heart, then in a fresh heart. In both specimens, the aortic and pulmonary roots were harvested en bloc. The coronary buttons were harvested from the aortic root and mobilised. A horizontal incision was made below the pulmonary valve (as in autograft procurement in the Ross procedure). The incision was extended on each side towards the aortic root. The ventricular septum was incised below the combined roots as close to the roots as feasible without damaging the leaflets and leaving enough tissue to sew to. The incision was brought around the aortic root, incising the aortic continuality. In the fresh specimen, the roots were rotated en bloc 180°, and the pulmonary root was anastomosed to the mitral annulus with a running polypropylene suture. The suture line closed the ventricular septum to the root box. The aortic root was then anastomosed to the infundibulum. Harvesting was successful in both hearts, and reimplantation was technically successful in the fresh heart. Histology showed no conduction tissue in the harvested root. This procedure may be an option in young patients with aortic valve disease candidates for a Ross procedure. Similar to a rotation of the outflow tracts, but in reverse, the dysplastic aortic valve could be recycled to the lower pressure pulmonary position, and it may avoid late reoperations on the RV-PA conduit. Experience from managing patients with tetralogy of Fallot shows that a pulmonary valve which isn’t perfect, but has a gradient not too high, can be very well tolerated without requiring reoperation or reinterventions. On the other hand, the durability of a homograft or other valued conduit on the RV-PA side after a Ross procedure is still unknown.

Rapid Response | Cardiac | Complexity in Brief: Translational Research in Cardiac Surgery

Bicuspid aortic valve: associated with aortopathy but protective for atherosclerosis?

J. Legué1, J. Lindeman1, E. Girdauskas2, T. J. Van Brakel1, R. Klautz1, L. Kroft1, N. Greisel1
1. Leiden University Medical Center (LUMC), Leiden, the Netherlands; 2. University Medical Centre Hamburg, Germany

Bicuspid aortic valve (BAV) is associated with an increased risk for aortopathy. The mechanism behind the pathological changes of the aorta in patients with BAV is still uncertain. Aortic dilatation in bicuspid aortic valve (TAV) is associated with features of cardiovascular aging, i.e. atherosclerosis, whereas the BAV aorta is characterised by immaturity of the ascending aortic wall, with a defect in differentiation of the vascular smooth muscle cells. It has been suggested that the same pathophysiological mechanism involved in the development of atherosclerosis is also involved in the progression of aortopathy in the BAV aorta. The relationship between BAV and atherosclerosis is not yet confirmed. The purpose of this study was to evaluate the association between aortopathy in BAV and the presence of atherosclerosis in the ascending aorta and coronary arteries.

A histopathology study was conducted comparing ascending aortic wall samples of 36 BAV patients (mean age 56.8 ± 8.7, 72% male, non-dilated n = 22, dilated n = 14) with 17 TAV patients (mean age 60 ± 8.9, 82% male, non-dilated n = 7, dilated n = 10). The aortic samples were graded for seven histopathological features, including atherosclerosis, using routine histologic stainings and immunohistochemistry. The extent of coronary artery atherosclerosis was evaluated by examining computed tomography (CT) scans without contrast to calculate coronary artery calcium scores and coronary angiograms to calculate CAGE scores.1, 2 Coronary artery calcium scores were compared between 36 BAV patients (mean age 60.1 ± 9.79, 83% male) and 27 TAV patients (mean age 58.88 ± 21.4, 78% male) who had undergone an aortic valve or aortic root replacement. We further compared the severity of coronary sclerosis using the CAGE scores of 114 BAV patients (mean age 59.2 ± 9.37, 78% male) with 72 TAV patients (mean age 62.8 ± 15.7, 58% male).

Histopathological analysis showed that the TAV aorta had features of intimal atherosclerosis whereas the BAV aorta showed no signs of atherosclerosis (Figure 1). A coronary artery calcium scores were significantly lower for BAV patients compared to TAV patients (CAGE 20 mean BAV 0.86 ± 2.3, TAV 1.55 ± 1.8, p = 0.003; CAGE 50 mean BAV 0.39 ± 1.025, TAV 1.14 ± 1.5, p = 0.001). Investigated BAV patients exhibited significantly less signs of atherosclerosis in the aorta. The CAGE scores and the CT-calcium scores were significantly lower in the BAV as compared to the TAV. It is plausible that having a BAV decreases the risk for atherosclerosis.

References

Juno Legué

Figure 1. MOCVAT, 11×, TAV, Left, features of an intimal atherosclerosis, Right, no features of atherosclerosis. Patients (CAGE 20 mean BAV 0.86 ± 2.3, TAV 1.55 ± 1.8, p = 0.003; CAGE 50 mean BAV 0.39 ± 1.025, TAV 1.14 ± 1.5, p = 0.001). Investigated BAV patients exhibited significantly less signs of atherosclerosis in the aorta. The CAGE scores and the CT-calcium scores were significantly lower in the BAV as compared to the TAV. It is plausible that having a BAV decreases the risk for atherosclerosis.

FACTS is grateful to Edwards Lifesciences SA for their generous support of this year's Young Investigator Award programme.
Rapid Response | Cardiac | Approaches to minimise stroke and improve survival in atrial fibrillation patients

Hybrid totally thoracoscopic and catheter ablation for long standing persistent atrial fibrillation confers excellent early outcomes

Adrian W Pick, Imran Khan, Andrew Kroger, Emily Kotschet, Stuart Healy, David Adam, Logan Bittinger
Department of Cardiac Electrophysiology, Monash Medical Centre, Clayton, Melbourne, Australia

Atrial fibrillation (AF) is now a pandemic in our ageing and expanding population. Despite Cox's development of a surgical procedure with near-universal curative success in 1987, widespread clinical practice has failed to adopt it. Meanwhile, catheter-based interventions have flourished and become the mainstay. For persistent AF, however, an isolated endocardial approach has significant limitations: procedural times can be long, the interventions are not without risk, and the outcomes are poor. By combining left atrial endocardial and epicardial interventions with staged mapping, we achieve the benefits of both approaches.

We report our first 25 consecutive patients undergoing a totally thoracoscopic (TT) maze procedure, followed at three months by electrophysiologic (EP) mapping. Selected patients had symptomatic, lone AF of greater than twelve months duration, having failed to revert despite multiple antihypertrophic agents. Patients were excluded if they had received prior EP intervention or required additional procedures for coronary revascularisation, valvular heart disease, or thoracic surgery.

Epicardial radiofrequency lesions are constructed around both pulmonary veins and across the roof and floor to complete a "Box" lesion. The left atrial appendage is then excised with a device (AtriCure, AtriCure Inc., USA) that also electrophysiologically isolates the base. Testing confirms lesion integrity. This unique approach requires only minimal surgical access and preserves the tenet of the "Cox Maze" lesion set, excluding only the mitral annular lesion. EP testing at three months assesses procedural success and can reinforce lesions if required.

Average patient age was 60 years (78% male). The main symptoms observed were palpitations (53%), fatigue (59%), chest pain (20%), and dizziness (23%). A history of transient ischemic attack was recorded in only one patient. There were no major in hospital complications (death, stroke or left atriooesophageal fistula) nor conversions to sternotomy. Operative times reduced during the series from 280 to 85 minutes with increasing procedural familiarisation. Perioperative AF was observed in only three patients and, on antithrombotics, all patients were discharged in sinus rhythm. Fourteen of 25 patients progressed to staged EP mapping, revealing that at three months, 13 (92.85%) were in sinus rhythm.

Connections were most common in the roof and floor lines followed by the right superior pulmonary vein (RSPV). Residual connections in the floor, roof and posterior wall did not correlate with failure to achieve stable sinus rhythm, bringing into question the significance of an incomplete mapping lesion, to which we are currently directing further investigation. Mapped connections did not directly correlate with procedural failure.

Our first series of hybrid ablation for long-standing, persistent AF reports excellent early outcomes, freedom from complications and near-universal pulmonary vein isolation. Deploying the AtriCure also facilitates exclusion and electrical isolation of auricular appendage. This evolving technique allows for staged lesion confirmation and provides critical electrophysiologic feedback, enabling the surgeon to refine the surgical intervention further and progressively improve outcomes.

**Table 1: Three-month EP testing results.**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Connected</th>
<th>Isolated</th>
<th>Success</th>
<th>Success</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Month EP Testing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LSPV</td>
<td>2</td>
<td>12</td>
<td>85%</td>
<td>100%</td>
</tr>
<tr>
<td>LPV</td>
<td>2</td>
<td>12</td>
<td>85%</td>
<td>100%</td>
</tr>
<tr>
<td>RSPV</td>
<td>5</td>
<td>9</td>
<td>64%</td>
<td>100%</td>
</tr>
<tr>
<td>RIPV</td>
<td>3</td>
<td>11</td>
<td>78%</td>
<td>100%</td>
</tr>
<tr>
<td>RDOF</td>
<td>3</td>
<td>7</td>
<td>50%</td>
<td>93%</td>
</tr>
<tr>
<td>FOOR</td>
<td>6</td>
<td>8</td>
<td>51%</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Figure 1. Bipolar clamping of the left pulmonary veins.**

**Figure 2. Application of the AtriClip to isolate the left atrial appendage.**

**Figure 3. Voltage map post endocardial ablation along the roof.**

Focus Session | Thoracic | TB and friends

Thoracic approach for pulmonary non-tuberculous mycobacterial diseases

Hirohisa Kato, Hiroyuki Ozumi, Jun Suzuki, Satoshi Takamori, Kaito Sato, Mitsuaki Sadahiro
Second Department of Surgery, Yamagata University, Yamagata City, Japan

Objectives
Non-tuberculous mycobacteriosis (NTM) has been increasing in recent years. NTM is an inflammatory disease that can lead to severe thoracic cavity adhesions, and open thoracotomy may be required for safe and curative resection. However, it is unclear whether open thoracotomy is truly essential. Thorascopy has increased in popularity due to its minimally invasive nature. We therefore adopted a thorascopic approach for NTM and evaluated our surgical outcomes.

Methods
This study involved 33 consecutive patients who underwent surgical resection and were ultimately diagnosed with NTM between June 2000 and April 2019. Pulmonary arteriovenous reconstruction was performed using a three-dimensional (3D) volume-rendering method, and the surgeon processed the 3D computed tomography (CT) image reconstruction. The surgical procedure was planned using the 3D CT reconstruction (Figure 1) and referenced during surgery. Lobectomy and wedge resection, as well as segmentectomy, were actively planned; theintersegmental veins on 3D images and infarction-deflation line were referenced to identify inter-segmental planes for segmentectomy (Figure 2). We primarily performed thorascopic surgery, usually via four-port access. The extent of adhesions was classified into three categories (none, moderate, severe), while the surgical outcomes and technique selection were evaluated retrospectively.

Results
Thirty, nine, and eleven patients underwent lobectomy, segmentectomy, and wedge resection, respectively. Severe adhesions were observed in 3 patients, moderate in 13 patients, and none in 17 patients, respectively. Median values for the procedure were 169 minutes for surgical time (range, 34-687 minutes), 42.5 mL for blood loss (range, 0-960 mL), 1 day for the duration of chest tube placement (range, 1-5 days), and 5 days for the postoperative hospital stay (range, 2-172 days). Complications occurred in 5 patients (15.2%); prolonged air leakage: 2, others: 3. Twenty patients had cavitated formation, atelectasis, disseminated shadows, or bronchiectasis on CT and underwent anatomical resections (lobectomy: 12, segmentectomy: 8). Meanwhile, eight out of ten patients with solid nodules on CT underwent wedge resection as diagnostic surgery for indeterminate tumours. Lobectomy and segmentectomy were performed significantly more commonly for the curative resection of NTM, except in the case of solid nodules (p < 0.001). Finally, 31 and 2 patients underwent thorascopic surgery and open thoracotomy, respectively. Three out of thirty-one thorascopy patients (9.7%) were converted to open thoracotomy due to severe adhesion (Mycobacterium xenopi, advanced lung cancer combined by Mycobacterium avium infection, and Mycobacterium avium infection on a background of previous tuberculosis).

Conclusions
Patients with NTM exhibited a lower extent of pleural adhesion than expected, and thorascopy could be performed safely in most cases. Wedge resection was performed to diagnose indeterminate tumours, while segmentectomy and lobectomy were performed as curative resection for NTMs.

**Figure 1. 3D CT reconstruction.**

**Figure 2. Thorascopic segmentectomy.**

**Figure 3. Voltage map post endocardial ablation along the roof.**
Renal protective effect of aortic balloon occlusion technique in total arch replacement with frozen elephant trunk

Bowen Zhang, Yanxiang Liu, Shenghua Liang, Yunfeng Li, Yaojun Duan, Yi Shi, Hongwei Guo, Xiaogang Sun 1. Cardiovascular Disease, Vascular Surgery Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Abstract | Vascular Disease | Strategy and long-term results in aortic valve repair

Reimplantation for annular stabilisation in bicuspid aortic valve repair of moderately dilated aortic roots: Is it justified?

Hiroshi Tanaka 1, Yuki Ikemoto 1, Koki Yokawa 1, Katsumi Yamatani 1, Soichiro Horiguch 1, Christian V Ghinea 1, Kenji Okada 1, Yutaka Onita 1, 1. Division of Cardiovascular Surgery, Department of Surgery, Kobe University, Japan; 2. Department of Cardiovascular Surgery, University of Colorado, USA

The principle of BAV repair includes annular suture annuloplasty. Valve-sparing root replacement is technically feasible. This may bring better long-term durability 3 and reduce the occurrence of aortic stenosis.

Except in Sievers type 0 BAV, an additional consideration in BAV repair is how to address a fused cusp which limits the mobility of the involved cusps. To obtain sufficient mobility, we shave and remove fibrotic tissue and calcification and incise the raphe along the annulus as not to create a perforation. We then reattach the raphe as low as possible inside the graft. After confirming cusp mobility, the non-fused cusp is excised to obtain an effective height of 9 mm. The raphe is subsequently closed with plication sutures in order to adjust the free margin length of both cusps (Figure 1&2).

Within our cohort there were no hospital deaths or embolic events in the follow-up period. Five-year freedom from greater than moderate aortic regurgitation was 94 ± 4%.

References

Rapid Response | Vascular | Do you like the elephant frozen?

Figure 1. Aortic balloon occlusion technique.

Figure 2. (Right) The bicuspid aortic valve was reimplanted in the Y-shaped valve. The revised annulus was sutured to the left ventricle. The commissures were repositioned to the aortic annulus and a cleft plication suture was performed. The raphe was then incised along the annulus.

Figure 3. Freedom from greater than moderate aortic regurgitation. Five-year freedom from greater than moderate aortic regurgitation was 94 ± 4%.

EACTS Daily News
Issue 3 Saturday 5 October 2019 17
### EACTS 2019 Agenda

#### Thursday 3 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Specialty</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Non Oncology</td>
<td>Room 3B, Pav 3</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Complex resections</td>
<td>Room 5A, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Surgery on the left ventricle – resect, repair and support</td>
<td>Auditorium 3+4</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:00</td>
<td>Congenital Rapid Response 1</td>
<td>Room 5B, Pav 5</td>
<td>Congenital Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>3rd International EACTS VAT Coordinator Symposium – Long-term management of VAD patients</td>
<td>Room 3C, Pav 3</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:00</td>
<td>Techno-College</td>
<td>Auditorium 1</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:15</td>
<td>Mediastinum and oesophagus</td>
<td>Room 3B, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:15</td>
<td>Outside the Box of Cardiothoracic Surgery</td>
<td>Room 108</td>
<td>Annual Meeting</td>
</tr>
<tr>
<td>08:15</td>
<td>Observational studies in the practice</td>
<td>Auditorium 6</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:15</td>
<td>Knowledge Generation in Congenital Heart Surgery</td>
<td>Auditorium 2</td>
<td>Congenital Disease</td>
</tr>
<tr>
<td>08:15</td>
<td>SAVR–new concepts and ideas you have not heard about before</td>
<td>Auditorium 3+4</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:15</td>
<td>Embracing the aortic arch</td>
<td>Room 5B, Pav 5</td>
<td>Vascular Disease</td>
</tr>
<tr>
<td>08:15</td>
<td>Sleeve resections</td>
<td>Room 5A, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>14:00</td>
<td>Jeopardy – Semi Finals</td>
<td>Room 5B, Pav 5</td>
<td>Annual Meeting</td>
</tr>
<tr>
<td>14:30</td>
<td>Current challenges in heart transplantation</td>
<td>Auditorium 8</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>14:30</td>
<td>Outcomes and controversies in mitral repair</td>
<td>Room 3B, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>14:30</td>
<td>Management of ACHD</td>
<td>Auditorium 2</td>
<td>Congenital Disease</td>
</tr>
<tr>
<td>14:30</td>
<td>Transplant abstract and focus session</td>
<td>Room 5B, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
</tbody>
</table>

#### Friday 4 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Specialty</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Late Breaking Clinical Trials – Part 1</td>
<td>Auditorium 7</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:00</td>
<td>Techno-College</td>
<td>Auditorium 1</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Coronary arteries in CHD</td>
<td>Auditorium 2</td>
<td>Congenital Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Clinical Trials in the practice: Focus on TAVI versus SAVR</td>
<td>Room 3C, Pav 3</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:00</td>
<td>TB and friends</td>
<td>Room 108</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Complexity in Brief: Translational Research in Cardiac Surgery</td>
<td>Auditorium 3+4</td>
<td>Adult Cardiac</td>
</tr>
<tr>
<td>08:00</td>
<td>TEVAR: Guns and Roses</td>
<td>Room 5B, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Update Thyrmic Surgery</td>
<td>Room 5A, Pav 5</td>
<td>Thoracic Disease</td>
</tr>
<tr>
<td>08:00</td>
<td>Training Suite: Congenital – Ross and the Reinforced Ross</td>
<td>Training Village</td>
<td>Congenital Disease</td>
</tr>
</tbody>
</table>

### Breaks

- **Break:** 12:00-13:00
- **Break:** 16:15-16:30
- **Break:** 14:00-14:15
14:00 Management of HLHS Auditorium 2 Congenital Disease
14:00 Nightmares in CT Room 108 Annual Meeting
14:00 Controversies and new findings in the treatment of tricuspid regurgitation Auditorium 7 Adult Cardiac
14:00 Guidelines Auditorium 1 Adult Cardiac
14:00 Thoracic surgery and basic science Room 5A, Pav 5 Thoracic Disease
14:00 Acute Type B Dissection Auditorium 6 Vascular Disease
14:00 Jeopardy – Final Room 5B, Pav 5 Annual Meeting
14:00 Thoracic Miscellaneous Auditorium 3+4 Thoracic Disease
14:00 Controversies and catastrophes in adult cardiac surgery Room 5C, Pav 5 Adult Cardiac
14:00 Training Suite – Coronary Training Village Adult Cardiac

**Saturday 5 October**

**08:00** Congenital Videos Auditorium 2 Congenital Disease
**08:00** Work in Progress Room 108 Annual Meeting
**08:00** Aviation medicine and high hazard occupational medicine Room 3C, Pav 3 Adult Cardiac
**08:00** Minimally Invasive Mitral Valve Surgery parade. Auditorium 8 Adult Cardiac
**08:00** Physiology for the cardiac surgeon Room 3A, Pav 3 Adult Cardiac
**08:00** Stroke in TAVI, Prevention and Treatment Auditorium 1 Adult Cardiac
**08:00** Systematic Reviews and Meta-Analysis: at the top of the evidence? Room 3B, Pav 3 Adult Cardiac
**08:00** Nurses & Allied Health Professionals Room 5C, Pav 5 Allied Health
**08:00** Lung Failure (Transplantation, ECMO and pulmonary endarterectomy) Room 5A, Pav 5 Thoracic Disease
**08:00** Thoracic aortic surgery in the young (DA VINCI SESSION) Auditorium 6 Vascular Disease
**08:00** Approaches to minimise stroke and improve survival in aortic stenosis patients Auditorium 3+4 Adult Cardiac
**08:00** Thoracic Mixed Room 5B, Pav 5 Thoracic Disease

**09:45** Leonardo Da Vinci: 500 years of a genius Auditorium 1 Annual Meeting

**11:45** Career Development Room 108 Annual Meeting
**11:45** A further step ahead: minimally invasive and Hybrid CABG Room 3B, Pav 3 Adult Cardiac
**11:45** BAV Repair Auditorium 8 Adult Cardiac
**11:45** Heart transplantation in 2019 Room 3A, Pav 3 Adult Cardiac
**11:45** ERAS Cardiac Surgery: First International Presentation of Guidelines Room 5C, Pav 5 Allied Health
**11:45** Ebstein Disease Auditorium 2 Congenital Disease
**11:45** Joint session ERS: MDT COPD and transplant Room 5A, Pav 5 Thoracic Disease
**11:45** Cerebral protection in aortic arch treatment Auditorium 6 Vascular Disease
**11:45** Optimising outcomes in mitral surgery Auditorium 3+4 Adult Cardiac
**11:45** Oncology Room 5B, Pav 5 Thoracic Disease

**11:45** Trial Update and Evidence Review Auditorium 1 Adult Cardiac
**11:45** Training suite: Introduction to mitral and four-cusp valve repair Training Village Adult Cardiac
**12:00** Residents Luncheon Terrace Annual Meeting

**Break**

13:30 Congenital Valve Auditorium 2 Congenital Disease
13:30 Strategy and long-term results in aortic valve repair Room 3C, Pav 3 Vascular Disease
13:30 Cardiac Surgery and translational basic science Room 108 Adult Cardiac
13:30 Choosing conduits for CABG: strategy in the secret for success Room 3B, Pav 3 Adult Cardiac
13:30 Heart failure surgeon at the cutting edge Room 3A, Pav 3 Adult Cardiac
13:30 TAVI vs. SAVR in low-risk patients Auditorium 1 Adult Cardiac
13:30 Lung Ultrasound workshop Room 5C, Pav 5 Allied Health
13:30 Advances in management of thoracic malignancies Room 5A, Pav 5 Thoracic Disease
13:30 Late complications of TEVAR Auditorium 6 Vascular Disease
13:30 TAVI – interesting new data will influence your practice Auditorium 3+4 Adult Cardiac
13:30 Dissecting aortic dissection Room 5B, Pav 5 Vascular Disease
13:30 EACTS-EACTA Joint Session: Repair of a regurgitant aortic valve Auditorium 8 Adult Cardiac

**Break**

15:15 Improving outcomes by a perioperative personalized blood management Room 3B, Pav 3 Adult Cardiac
15:15 SAVR – long-term results, emphasis on particular subgroups Room 3A, Pav 3 Adult Cardiac
15:15 Congenital Miscellaneous Auditorium 2 Congenital Disease
15:15 Help! Trainee in Trouble Room 108 Annual Meeting
15:15 Technical pearls in mitral valve repair: artificial chordae adjustment Auditorium 1 Adult Cardiac
15:15 Multidisciplinary tumour board Room 5A, Pav 5 Thoracic Disease
15:15 “Here we go again” – Strategies in re-do thoracic aortic surgery Auditorium 6 Vascular Disease
15:15 Nurses & Allied Health Professionals Room 5C, Pav 5 Allied Health
15:15 Predicting and managing Mechanical Circulatory Support-related complications Auditorium 3+4 Adult Cardiac
15:15 Do you like the elephant frozen? Room 5B, Pav 5 Vascular Disease
Sternal band and plate fixation superior to stainless steel wires

Alistair Royse, Doa El-Ansary, William Hoang, Lynda Tivendale, Stuart Boggett, David Canty, Yang Yang, Colin Royse
Department of Surgery, The University of Melbourne and Royal Melbourne Hospital & Department of Health Professions (Physiotherapy), Swinburne University, Melbourne, Australia

Abstract | Cardiac | Late Breaking Clinical Trials – Part 2

A basic principle of orthopaedic surgery is that good bone healing requires minimisation of bone edge motion at a fracture site. But after sternotomy for cardiac surgery, patients are encouraged to breathe deeply and cough, making rigid bone fixation particularly difficult. In most cases, cardiac surgery uses stainless steel wire cerclage whereas wire fixation for other forms of surgery has generally been abandoned. Why is this? One of a number of commercially available “band and plate” fixation systems for use with sternotomy was subjected to a prospective randomised trial and compared to conventional “figure of 8” stainless steel wire cerclage. Motion of the sternal edges was detected dynamically using high-frequency ultrasound video recording during coughing, and the maximum edge separation was measured at four sites of the sternum. Conventional radiologic imaging is a static test performed at rest, whereas coughing produces high intrathoracic pressure and results in a maximum distraction force acting on the sternum. Clinically, it is usually considered that moderate bone healing would have occurred by the sixth postoperative week. Fifteen patients were randomised, and after withdrawal of consent or death, 25 remained in the plates group and 22 in the wires group. There was a good match of demographic and operative risk factors. The EuroSCORE II for the plates group was 2.1 ± 2.5 vs 1.8 ± 2.6 for the wires group (p = 0.685). The former required more time to implant (16.2 ± 6.7 vs 12.6 ± 5.8 minutes, p = 0.045). The primary endpoint was ultrasound-detected bone edge movement of > 2 mm at ≥ 2 of 4 sites assessed, 6 weeks postoperatively. This was present in 4% and 32% of the plates and wires groups, respectively (p = 0.018). A number of secondary endpoints were also analysed at the 12th postoperative week. Ultrasound-detected bone edge movement was 0% for the plates group and 25% for the wires group (p = 0.014), while evidence of early bone formation or greater on CT was 21% /14% (p = 0.076). Separation of bone edges at rest on CT of > 2 mm at ≥ 2 of 5 sites was 38% and 71% for the plates and wires groups, respectively (p = 0.036). Postoperative quality of recovery score (PhysioCRR) was also measured, whereby a patient is deemed “recovered” if they attain a postoperative score equal to or better than their baseline preoperative score. Overall there was no difference with recovery (71% for the plates and 52% for the wires group, p = 0.099). However, for the pain domain of the PhysioCRR, there was improved recovery of 50% for the plates group and 67% for the wires group (p = 0.004). These data suggest that the band and plate system has improved bone fixation compared to conventional stainless steel wire cerclage.

References

Early results from a prospective European trial on decellularised allografts for aortic valve replacement – The ARISE Study

Samir Sarikouch
Hannover Medical School, Department of Cardiothoracic Surgery, Hannover, Germany

Aortic valve replacement (AVR) in children and young adults often entails a difficult choice between a complex, multi-stage procedure such as the Ross procedure and life-long medication with blood thinners and their inherent risks once a mechanical prosthesis is chosen. Decellularised aortic homografts (DAH) may constitute an additional AVR option in such patients as they hold the potential to overcome the high early failure rate of allogenic and xenogenic aortic valve prostheses in children and young adults.

In a European-Commission funded project led by the Hannover Medical School, nine hospitals, six tissue banks and an innovative biotech company (who provided the decellularisation service) came together for the world-wide first prospective multi-centre study on cell-free allografts for aortic valve replacement – The ARISE Study (S Sarikouch, Hannover, for the ARISE Investigators), held between 10/2015 and 10/2018 (mean age 33.6 ± 20.8 years; 45% of the patients underwent previous cardiac operations). There were 2 early deaths (1 LCA thrombus on day 3 and 1 ventricular arrhythmia 5 hours postoperatively) and 1 late death due to endocarditis 4 months postoperatively, resulting in a total mortality of 2.08%. One pacemaker implantation was necessary and 1 DAH was successfully repaired after 6 weeks for relevant early reurgitation. After a mean follow-up of 1.54 ± 0.81 years, the primary efficacy endpoints of peak gradient (mean 11.18 ± 7.5 mmHg) and regurgitation (mean 0.42 ± 0.49, Grade 0–3) were excellent. At 2.5 years, freedom from explantation/endocarditis/bleeding/stroke were 99.4 ± 1.1 / 99.4 ± 0.6 / 99.1 ± 0.9 / and 99.2 ± 0.8%, respectively.

Figure 1 shows ARISE Registry Data of all 223 DAH implanted to date in comparison to recently published meta-analysis data for several AVR options in young adult patients. Figure references: a) Elnet et al. Circ Cardiovasc Qual Outcomes. 2018;11(12):e004748; b) Korteland et al. Eur Heart J. 2017;38(45):3370-3377; c) Etnel et al. Circ Cardiovasc Qual Outcomes. 2019;12(2):e005481. There will be also a second presentation by the ARISE Paediatric study group just before in Auditorium 2 focusing on paediatric aortic valve replacement: Saturday, 14:45, Auditorium 2 – “Paediatric aortic valve replacement using decellularised aortic grafts” (S Sarikouch, Hannover, for the ARISE Paediatric Investigators).

References
1. www.arise-cardiac.org
Longer-term outcomes for heart surgery significantly better than other procedures, new evidence finds

Patients with heart disease who have surgery have significantly better longer-term outcomes than patients opting for heart stents or transcatheter aortic valve implantation (TAVI), according to new evidence presented today at the EACTS Annual Meeting in Lisbon.

The findings, to be presented at the EACTS conference, the largest heart patient database in the world, include:
- For several decades bypass surgery (CABG) has been known to offer better survival and a much reduced risk of subsequent myocardial infarction (heart attack) and need for further interventions compared to stents. It was also thought that patients with less severe disease could do as well with stents. However, a new study (Excel: Everolimus-Eluting Stent of Bypass Surgery for Left Main Artery Disease) now suggests that even patients with less severe forms of this disease who have bypass surgery have a significantly better chance of surviving for five or more years if they choose surgery. The study not only shows that surgery gives patients around a one-third improved survival rate compared to stents but that at 5 years that survival benefit appears to be accelerating.
- The results of the Partner 2 Trial, to be presented for the first time in Europe, found that the five year outcomes for patients with ‘intermediate’ operative risk having surgical aortic valve replacement (SAVR) were significantly better than for those having the TAVI procedure. This means that for every 100 patients dying within 5 years of having the TAVI procedure, 70 people would have died having had surgery.
- An analysis in Italy of the long-term outcomes of TAVI vs SAVR led by Dr Barli, Cuneo, Italy, found that while early results are promising for TAVI, from 40 months onwards TAVI has significantly worse outcomes than conventional surgery. TAVI procedures are undertaken by both cardiologists and surgeons.
- The latest update from the North American TAVI registry reveals that the ‘real world’ outcomes for patients are worse than those of the randomised trials. Data also shows that complication rates are not decreasing with time even though the numbers of TAVI procedures are growing. Discussing the findings of the Excel study, Professor David Taggart, Professor of Cardiovascular Surgery at the University of Oxford, said: “The EXCEL study looked at the best treatment for a potentially particularly lethal form of coronary artery disease called ‘Left main disease’ as it affects the most important blood vessel supplying blood to the heart muscle. While it is widely accepted that surgery is the right procedure for a patient, for less severe patterns of disease that bypass surgery is best it was also previously thought that for less severe forms of disease the same result could be obtained with stents. However, the EXCEL study, the most definitive study of its kind for this type of disease, now shows that, assuming a patient is relatively fit, their chances of being alive after five years are dramatically better – by almost one-third – if they have heart bypass surgery rather than stent treatment. This confirms the importance of doing randomised clinical trials to ensure that the most potentially innovative techniques are actually as safe as the tried and tested standard techniques and that newer techniques must be implemented with caution. If a patient has blockages in the main heart artery or in more than two arteries and especially if the patient is diabetic, I strongly recommend that they get the opinion of a surgeon. Thankfully, in the UK, we have strong ‘Heart Teams’ consisting of cardiologists, surgeons and other experts who working closely together can recommend the best treatment to the individual patient. However, as most patients are not able to make the decision to recommend treatment is made by a cardiologist and, regrettably, the patient does not get any opinion from a surgeon.

The new findings from several international studies raise questions about whether the innovations for Left Main Artery Disease (LMAD) now introduced – such as the Excel (AfroCaTS) study not only shows that the long-term survival rates for patients who have surgical aortic valve replacement are significantly better than for those who have the TAVI procedure.

Dr Rita Redberg, Cardiologist at University of California San Francisco, who will co-chair the debate on Saturday 5 October, said: “These new findings highlight that some patients are living longer if they opt for surgery over some other techniques. This should focus minds: when advising on the right procedure for a patient, we need to know and share the data on risks and benefits. While avoiding surgery seems attractive in the short run, this short term benefit pales if it is at the price of longer survival with surgery. Patients will benefit from having their risks and benefits explained by a multi-disciplinary heart team to ensure they are able to access the best and personalized treatment. Innovation is vital and it’s how practice evolves but we must ensure innovation is introduced safely and is best for patients. We should avoid a race to widely adopt new techniques until such innovations can demonstrate equivalent sustainable results to established surgical techniques.”

References

This initiative is a wake-up call for joint efforts to develop south–south cooperation. You are invited to join the AfroCaTS Working Group.

Reference


African Cardiothoracic Surgery Database (AfroCaTS)

Charles Yankah; PASCaTS (www.pascats.com)

Background

Cardiac surgical care in sub-Saharan Africa (SSA) is worsened by the limited capacities of infrastructure, manpower and funding.

One of our concerns is the lack of reliable data on surgical procedures on which to base effective concepts for developing sustainable cardiac surgical programmes. Mitral valve repair constitutes 10% of valve procedures in Africa and only 2% of children with CHD have access to surgery. It is timely and appropriate, therefore, to ask ourselves where we are?

PASCaTS has initiated a database (AfroCaTS Database) for cardiothoracic surgeries performed by local and foreign cardiac teams which could be used: 1. For clinical and academic research for the improvement of medical/surgical management of patients; 2. As a working instrument to evaluate the burden of disease and to develop strategies for prevention and treatment of cardiovascular diseases and their related morbidities; 3. For developing useful guidelines for clinicians and policy makers in order to plan appropriate cardiovascular disease prevention and therapy.

This initiative is a wake-up call for joint efforts to develop south–south cooperation. You are invited to join the AfroCaTS Working Group.
Endoscopic mitral repair for degenerative mitral regurgitation: Effect of disease complexity on short and long-term outcomes

We set out to compare, in a prospective cohort study, the long-term clinical and echocardiographic outcomes of patients undergoing minimally invasive, endoscopic mitral repair for simple (posterior leaflet prolapse) versus complex disease (anterior/bilateral prolapse).

Two hundred and forty-five consecutive patients underwent minimally invasive, endoscopic mitral repair for severe degenerative mitral regurgitation (MR) through a right, endoscopic approach (n = 145 simple, n = 100 complex). The most common repair technique was annuloplasty + artificial chordae (84%, n = 121 for simple vs 88%, n = 88 for complex, p = 0.3) with the other patients receiving more traditional repair techniques. Patients were prospectively followed for a maximal duration of nine years. Patients’ characteristics were well balanced between groups (age: 63 ± 12 years simple, 59 ± 15 years complex, p = 0.06; male: 71%, n = 103 vs 68%, n = 68, p = 0.66; LVEF: 62 ± 7% simple vs 62 ± 7% complex, p = 0.9; NYHA ≥ 3: 31%, n = 45 vs 34%, n = 34, p = 0.6; MR grade ≥ 3: 100%, n = 145 vs 100%, n = 100, p = 1).

The 30-day/in-hospital mortality was similar (0%, n = 0 simple vs 1%, n = 1 complex, p = 0.2). Both groups had similar rates of early post-operative complications: myocardial infarction (1.4%, n = 2 vs 0%, n = 0, p = 0.2); neurological complications (1.4%, n = 2 vs 0%, n = 0, p = 0.2); re-operation for bleeding (0.7%, n = 1 vs 3%, n = 3, p = 0.2); intensive care unit length of stay (1 IQR 1.1 days vs 1 IQR 1.1 days, p = 0.7). Early in-hospital residual mitral regurgitation was similar between groups (MR grade ≤ 1.100%, total n = 245, for both groups, p = 1.0). Late survival (83% for simple vs 86% for complex, p = 0.6) and actuarial freedom from re-operation or valve-related complications (100% vs 88%, p = 0.07) at nine years were similar between both repair groups. Actuarial freedom from NYHA > 2 (90% for simple vs 100% for complex, p = 0.12) or MR > 2 (97% for simple vs 98% for complex, p = 0.8) at nine years was similar for all patients.

Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile?

Thymoma recurrence is described in 10–30% of cases after surgical resection, and adjuvant surgery for pleural relapses (TPR) is often part of a multimodal treatment. Hyperthermic intra-thoracic chemotherapy (HITHOC) following macroscopic radical surgery is an option that combines effects of mild hyperthermia with those of chemotherapy agents. The aim of our study is to evaluate the effectiveness of surgery + HITHOC, compared with surgery-alone, in TPR treatment.

We retrospectively collected data of all patients who underwent surgery for TPR in our centre from 2005 to 2017. Relapses were treated by partial pleurectomy with radical intent, followed by HITHOC when not contraindicated (preoperative impairment of cardiac or renal function; previous extended resection during the primary surgery; large involvement of pericardium or diaphragm). Patients were divided in two groups: surgery+HITHOC and surgery-alone. We collected demographic and clinical data and analysed postoperative results together with oncological outcomes.

Forty patients (27 surgery+HITHOC, 13 surgery-alone) with a mean age of 49.8 ± 13.7 years were included in this study. Perioperative mortality was nil. We experienced 33.3% perioperative mortality in the surgery+HITHOC group compared with 23.1% in the surgery-alone group (p = 0.71). The overall survival was comparable between the two groups (p = 0.139), while the local disease-free interval (DFI) was 88.0 ± 15 months in the surgery-HITHOC group and 67.0 ± 19.5 months in the surgery-alone group (p = 0.046). The analysis of factors affecting the outcomes revealed that surgical radicality is related with a better overall survival (p = 0.040) while the local DFI was significantly influenced by HITHOC perfusion after surgery (p = 0.049).

This work confirms the safety and feasibility of HITHOC in TPR treatment and, most importantly, indicates that HITHOC perfusion following surgery is associated with longer local disease-free time compared to surgery alone.
Can Marfan syndrome and Loeys-Dietz syndrome be treated in the same way?

Yoshimasa Seike1, Hitoshi Matsuda1, Yusuke Inoue1, Takayuki Shijyo1, Atsushi Omura1, Yosuke Inoue1, Takayuki Shijyo1, Atsushi Omura1, Kyokun Uehara1, Hiroko Morisaki2, Takayuki Morisaki3, Junjiro Kobayashi1

1. Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan; 2. Department of Medical Genetics, Sakaikiwa Heart Institute, Japan; 3. Department of Clinical Engineering, Tokyo University of Technology/School of Health Sciences, Japan

Focus Session | Vascular | Thoracic aortic surgery in the young (DA VINCI SESSION)

The 2010 revised Ghent nosology for Marfan syndrome (MFS) focused more on aortic root dilatation and/or dissection, ectopia lentis and the presence of fibrillin-1 gene (FBN1) mutations, which are the major causes of MFS1,2. However, Loeys-Dietz syndrome (LDS) is a recently recognised hereditary aortic disease (HAD) caused by mutations in transforming growth factor-beta receptor (TGFBR) 1, TGFBR2, SMAD3 and transforming growth factor-beta 2 (TGFBR2). Both MFS and LDS have commonly categorised in the same group for their syndromic forms of thoracic aortic aneurysms and dissections, which have the greatest influence on the prognosis. However, according to the recognition of the difference in mutations and accumulation of surgical results, the difference in postoperative presentation between MFS and LDS should be discussed. In this study, the clinical results of these HADs are compared to determine the differences in surgical outcomes in young adult patients carrying these gene mutations, MFS and LDS.

We reviewed 368 patients < 50 years who underwent surgery for thoracic aortic diseases between 1988 and 2019, and enrolled 99 MFS patients (26.9%: 42 men, 33 ± 7.5 years of age) and 28 LDS patients (7.6%; 16 men, 29 ± 10 years of age) after the genetic screening.

The freedom from all-cause mortality rates at 10 and 15 years were similar between the two groups (MFS, 98% and 91%; LDS, 96% and 96%; p = 0.55). The rates of freedom from reintervention at 10 and 15 years were significantly lower in the LDS group (83%/69%) than in the MFS group (98%/48%) (p = 0.015). The aortic root was untreated in five patients (5.1%) with MFS and five patients (17.9%) with LDS (p = 0.07). The aortic arch was untreated more frequently in the MFS group (74 patients, 74.7%) than in the LDS group (10 patients, 35.7%) (p < 0.001; Figure 1).

In conclusion, LDS revealed higher rates of reoperation and aortic dissection after initial surgery than MFS. Extensive initial operation and early reoperation are more critical in LDS to avoid fatal aortic event. In MFS, aggressive arch surgery is controversial in patients without dissection for low possibility of expansion.

References
Impact of concomitant cardiac procedures during implantation of long-term continuous-flow LVADs: A European Registry for Patients with Mechanical Circulatory Support (EUROMACS) analysis

Antonio Loforte1, Gregorio Gliozzi, Felix Schönbrath, Carlo Mariani1, Ivan Netuka, Yuriy Pyda, Jan Green, Martin Gretsch, Kurt Meyns, Theo De By2, Davide Pacini1
1. 3. Ospedale S. Orsola Malpighi, University of Bologna, Bologna, Italy; 2. German Heart Institute Berlin, Berlin, Germany; 3. Institute for Clinical and Experimental Medicine, Prague, Czech Republic; 4. National Research Cardiac Surgery Center, Astana, Kazakhstan; 5. Heart and Diabetes Center North-Rhine Westphalia, Pforzheim, Bad Oeynhausen, Germany; 6. Heart and Diabetes Surgery Center, Astana, Kazakhstan; 7. EACTS, EUROMACS, Windsor, United Kingdom; on behalf of EUROMACS Investigators.

TAVI is associated with less patient–prosthesis-mismatch than surgical AVR in severe aortic stenosis: A systematic review and meta-analysis

N. Bonaros, L. Stastny, M. Koffer, G. Abi Khalil, B. Ignatiuk, G. Erdey, M. Grimm, F. Barilli
Innsbruck Medical University, Austria

TAVI has shown to be at least non-inferior to surgical aortic valve replacement (sAVR) in terms of mortality for the treatment of low, intermediate- and high-risk patients with severe aortic stenosis (AS). Our current study sought to assess whether there is a difference on echocardiographic parameters such as patient prosthesis-mismatch, residual gradients and effective orifice area up to two years after TAVI and sAVR.

We conducted a random-effect model meta-analysis of randomised controlled trials that compared TAVI and sAVR. The primary outcome was post-procedural patient-prosthesis-mismatch (PPM). Secondary outcomes were post-procedural and effective orifice area (EOA), paravalvular gradient (PPG) and moderate/severe paravalvular leak (PVL).

We identified five trials with a total of 5,552 participants with AS, including 2,777 patients randomized to TAVI and 2,775 randomized to sAVR. TAVI was associated with a significant 35% relative risk reduction (RR = 0.65, 95% CI [0.50–0.84], p = 0.009) compared to sAVR and PPM with homogeneity across all trials (p for interaction = 0.351). The effect was more evident in self- rather than balloon-expandable valves (p = 0.029). Similar results were found in terms of post-procedural EOA (RR = 0.53, 95% CI [0.43–0.62]), and residual gradients (PPG ≤ 0.54, 95% CI [0.40–0.69]). As expected, TAVI demonstrated higher rates of moderate/severe PVL (P = 0.41, 95% CI [32.2–16.6]).

The results were sustainable at two years; there were pooled increased EOA (0.48 [95% CI [0.24–0.72]), and pooled decreased residual gradients (0.58 [95% CI [0.77–0.25]) in favour of TAVI. The incidence of moderate/severe PVL remained lower in sAVR patients (10.30% [95% CI [4.80–22.46]). The relative risk reduction of overall mortality was 7% at 1 and 4% at 2 years as compared to sAVR, and was not statistically significant (1 year: p = 0.667; 2 years: p = 0.513). Similarly, TAVI was compared as sAVR was associated with an 11% (p = 0.808) and 4% (p = 0.626) relative risk reduction for cardiovascular mortality at 1 and 2 years, respectively.

The echocardiographic results obtained by the meta-analysis may explain the equipoise between the two treatment arms in terms of mortality: TAVI has the advantage of low residual gradients and lower rates of PPM but the disadvantage of higher rates of paravalvular regurgitation. both conditions can be associated with increased mortality, any improvement on the incidence of PVL in TAVI valve or PPM in a surgical valve may lead to the cards being reshuffled again.

We demonstrated that there are differences in EOA, transvalvular gradients and PPM not only between the two treatment arms but also within the TAVI valves. Self-expandable valves have been found to be more advantageous than balloon-expandable valves. This is supported by registry data in the literature. However, literature data demonstrate a higher incidence of PVL in self-expandable valves, though this has not been investigated in our analysis. From this point of view our meta-analysis provides the first evidence that patients at risk for PPM may benefit from transcatheter therapy especially by using a self-expandable valve. On the other hand, patients at risk for PVL should be treated by either balloon-expandable valves or conventional surgery. To summarise, our meta-analysis suggests that TAVI is associated with a lower risk of PPM, as well as higher EOA and lower residual gradients through two years of follow-up. This was accompanied by a higher incidence of moderate/severe PVL as compared to sAVR. Future research should focus on the effect of echocardiographic differences on clinical outcomes.

References
Impact of pulmonary artery reduction during an arterial switch operation: 14-year follow-up

Fernanda Lübe Antunes Pereira¹, Cristiane Nunes Martins¹, Roberto Max Lopes², Matheus Ferber Drummond², Fernando Antonio Fantini², Erika Correa Vrandecic², Mario Oswald Vrandecic Peredo², Bayard Gontijo Filho¹ ¹. Síncora Institute, Department of Cardiovascular Surgery; ². Department of Pediatric Cardiology; ³. Department of Cardiology, Belo Horizonte, Brazil

The arterial switch operation (ASO) has become the surgical procedure of choice to repair transposition of the great arteries (TGA) in neonates and infants, with excellent early- and mid-term results and satisfactory overall survival and functional status. From January 1998 until December 2018, 425 patients underwent ASO in our institute. In our experience we found that significant pulmonary artery/aorta size (PA/Ao) discrepancy plays an important role in the development of disproportionate neo-aortic root growth and valve regurgitation after ASO, especially in patients with complex variants of TGA and aortic arch anomalies association. Since February 2004 we started using PA reduction to manage severe PA/Ao mismatch at the time of ASO, and this study evaluated the impact of this technique in the mid- and long-term follow-up of these patients. Thirty-one patients were followed up with clinical and image exams. Echocardiography findings were reviewed and Z-scores were recorded to evaluate incidence and progression of neo-aortic root dilatation and valve regurgitation. PA reduction was indicated in patients considered to have severe PA/Ao mismatch (> 2:1 ratio) at the time of ASO and was achieved by resecting a 3-4 mm rectangular flap of the PA wall, reducing the entire pulmonary root including downsizing the valve annulus, achieving a symmetrical total reduction of the neo-aortic root and more harmonic anastomosis with the ascending aorta.

Median follow-up time was eight years (range 54 days to 14 years). The mean difference between Z-scores of the pulmonary annulus (before ASO) and neo-aortic annulus (at latest follow-up) were 2.05 (95% CI 1.70 to 2.39, p < 0.0001). Mean Z-scores for the sinus of Valsalva was +0.29 ± 1, the sinotubular junction +0.71 ± 0.6, and ascending aorta +1.09 ± 0.7. There was no severe dilatation of the neo-aortic annulus, neo-aortic root or ascending aorta during follow-up. Neo-aortic valve regurgitation was none or mild in 93% of patients. The pathophysiological mechanisms for neo-aortic root dilatation and development of moderate- to severe neo-aortic regurgitation are poorly understood, and probably multifactorial. We believe that preservation of the aortic diameter and valve function with PA reduction may be explained by reduction of the initial size of the neo-aorta and geometric concordance between the neo-aortic root and ascending aorta anastomosis, avoiding the distortion generated by suture trimming and resulting in a better hydraulic flow pattern, reducing the impact on the arterial wall.

PA reduction proved to be a feasible and low-risk procedure to approach PA/Ao mismatch in the ASO. Mid- and long-term follow-up showed a tendency towards stabilisation of the neo-aortic root dilatation and satisfactory valve performance after the procedure. Nevertheless, further investigation is required with a larger population and longer-term follow-up. Furthermore, drawbacks regarding the technique must be taken into consideration.

Figure 1. Schematic illustration of great vessels before and after pulmonary artery (PA) reduction during the arterial switch operation (ASO). Left: disposition of the great vessels during ASO. PA/aorta (Ao) mismatch and indication of PA reduction site. Right: the aspect of great vessels during ASO, after PA reduction, with posterior sinus of Valsalva reduction suture and leaflets redundancy in the neo-Ao as well as reconstruction of sinus of Valsalva in the neo-PA.

Figure 2. Comparison between the Z-score values of valve annulus before and after the arterial switch operation with pulmonary artery reduction.

Figure 3. Schematic illustration of the neo-aorta (neo-Ao) after arterial switch operation in the presence of preoperative pulmonary artery (PA)/Ao mismatch. The top image shows neo-Ao in patients that were not submitted to PA reduction, showing size discrepancy in anastomosis between the neo-Ao root and ascending aorta. The lower image shows neo-Ao in patients submitted to PA reduction, showing geometric concordance of the anastomosis.

Figure 4. Angiotomographic images of neo-aorta of different patients submitted to pulmonary artery reduction in the long-term follow-up after an arterial switch operation. Patient B had angioplasty to correct recoarctation of the aorta. Patient C had interruption of the aortic arch associated with transposition of the great arteries.

Figure 5. 3D angiotomography reconstruction of neo-aorta in different patients submitted to pulmonary artery reduction after an arterial switch operation. The patient on the right had angioplasty to correct recoarctation of the aorta.
Improving outcomes by a peripherally personalized blood management: Preoperative patient optimisation prior to cardiac surgery

Milan Milojicic, Department of Cardiothoracic Surgery, Enamur University Medical Center, Rotterdam, Netherlands; and Department of Cardio Surgery, Dedinje Cardiovascular Institute, Belgrade, Serbia

Abstract | Cardiac | Improving outcomes by a peripherally personalized blood management

Prehabilitation for surgery in lung cancer: is it worth it?

Kalliopi Athanassiadi, D. Magouliotis, E. Batsaki, K. Glyoun, A. Sfetsou, I. Sigala, S. Zakynthinos

Department of Thoacic Surgery; Department of Physiotherapy & Pulmonology, EVANGELISMOS General Hospital, Athens, Greece

Abstract | Thoracic | Oncology

Outcomes of bidirectional Glenn procedure in patients less than 3 months of age

Noritaka Ota, Tsuyoshi Tachibana, Hidetsugu Asai, Jin Igarashi, Toshitake Asahi, Hiroko Izutani

1. Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Ehime, Japan; 2. Department of Cardiovascular Surgery, Kangawa Children's Medical Center, Yokohama, Japan

Abstract | Congenital | Congenital Miscellaneous

Improving outcomes by a peripherally personalized blood management: Preoperative patient optimisation prior to cardiac surgery

Milan Milojicic and Richard L. Pragar from the University of Michigan, USA

Abstract | Cardiac | Improving outcomes by a peripherally personalized blood management

Prehabilitation for surgery in lung cancer: is it worth it?

Kalliopi Athanassiadi

Noritaka Ota

Japan, for reference, we also reviewed the data from 204 patients who had undergone BDG procedure aged more than 4 months in the same period (‘older’ group).

The younger and older groups were aged 99.7 ± 14.3 months and 303.5 ± 80.5 months respectively (p < 0.001). The younger group was significantly heavier (23.8 ± 4.7 kg vs. 17.5 ± 5.2 kg, p < 0.0001) and had a higher BMI (20.4 ± 3.6 vs. 18.5 ± 4.2, p < 0.01) compared to the older group.

All patients had undergone previous palliative treatments, including surgical procedures, medical therapies, and/or best supportive care. The median duration of previous palliative care was 6 months (range: 1-12 months) in the younger group and 12 months (range: 6-24 months) in the older group.

The main surgical procedures performed included pulmonary lobectomy (67% in the younger group vs. 33% in the older group), extracorporeal membrane oxygenation (ECMO) (21% vs. 3%, respectively), and median sternotomy (23% vs. 42%, respectively). The median hospital stay was 10 days (range: 5-20 days) in the younger group and 15 days (range: 8-27 days) in the older group.

The postoperative complications rate was significantly higher in the younger group compared to the older group. The most common complications were bloodstream infections (30% vs. 5%, respectively), arrhythmias (23% vs. 6%, respectively), and pulmonary complications (17% vs. 3%, respectively). The early mortality rate was 10% in the younger group vs. 5% in the older group, with no significant difference between the two groups (p = 0.57).

The Kaplan-Meier estimates of Fontan completion rates were 95.5% ± 10% and 92.5% ± 10% in the younger and older groups, respectively (p = 0.4). The overall survival rate was 96% ± 4% and 90% ± 6% in the younger and older groups, respectively (p = 0.39).

In conclusion, the bidirectional Glenn procedure appears to be a safe and effective palliative treatment option for young patients with congenital heart disease, providing significant improvements in terms of surgical outcomes, postoperative complications, and overall survival rates. Further studies are needed to evaluate long-term outcomes and explore potential improvements in surgical techniques and perioperative care.
34th EACTS Annual Meeting
Barcelona, Spain
8-10 October 2020

Abstract deadline
30 April 2020

To find out more or to register for the event visit www.eacts.org

Raising Standards through Education and Training
Thoracoscopic lobectomy for non-small cell lung cancer in patients with impaired pulmonary function: Analysis from a national database

Stefano Bongiolatti
Thoracic Surgery Unit, Careggi University Hospital, Florence

ATS-lobectomy (ATS-L) has become a safe and effective alternative to conventional thoracotomy, and is associated with a shorter length of stay, less postoperative pain, fewer postoperative complications, better compliance with adjuvant chemotherapy and more preserved pulmonary function. Some relevant papers have demonstrated that ATS-L is feasible in patients with poor lung function, and is associated with better results than thoracotomy, but few multicentre studies have investigated the outcomes in this fragile population. Furthermore, current pre-operative guidelines for risk assessment were established according to the evidence obtained from large studies on patients undergoing lung resection through open thoracotomy, and so data are lacking on the effective impact of ATS-L on post-operative lung function and post-operative mortality and complications. The aim of our study was to show the mortality, overall-and pulmonary complication rate and the impact of impaired pre-operative pulmonary function on these outcomes, analysing data from the Italian VATS Group Database.

The Italian VATS Group Database is a multicentre, web-based data system for collecting and reporting clinical characteristics, patterns of care, and outcomes data on NSCLC patients treated with a VATS-L. The Italian VATS Group has maintained this prospective database since January 2014. At the time of the latest report, there were more than 55 participating centres (general thoracic surgery units or services, not individual surgeons) and about 8,000 collected cases.

Our study population consisted of patients who received VATS-L with curative intent as the primary procedure for NSCLC at VATS-Group participating centres, included in the VATS Group database between 1 January 2014 and 31 December 2018. Then, we compared two Groups based on pre-operative lung function: Group A comprised patients with normal pre-operative lung function, while Group B included patients with limited pre-operative lung function. Impaired lung function was defined as pre-operative FEV1 less than 60% or pre-operative DLCO% less than 60% or both. The threshold of 60% was chosen based on previous studies demonstrating that patients with these FEV1 or DLCO% values have an increased risk of morbidity and mortality after lung resection. Based on this functional limit, we compared post-operative results on n = 224 patients with pre-operative FEV1% less than 60%; n = 645 DLCO% less than 60% and n = 60 patients with both values lower than 60%.

Although we performed a retrospective analysis, our outcomes could be interpreted as generally adequate and the multicentre nature of this study. Briefly, we observed no statistical difference regarding pre-operative mortality between patients with normal and poor lung function; patients with limited lung function developed more overall and respiratory complications and the limited lung function was a strong risk factor for overall and pulmonary complications. Thus, ATS-L is high-risk patients is safe and feasible. Pre-operative values of lung function must be still considered as the cornerstone of the patient selection algorithm and risk stratification should also be performed before minimally invasive lung lobectomy.

References
Mid- to long-term follow-up of pulmonary valve replacement with Biointegrate injectable valve

Simone Ghiselli, Cristina Carro, Nicola Uricchio, Giuseppe Annoni, Stefano M Marianeschi
1. Cardiac surgery, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
2. Cardiac surgery, ASST Pio Giovanni XXII, Bergamo, Italy
3. Pediatric cardiology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Abstract | Congenital | Congenital Valve

The aim of our study is to evaluate, retrospectively, the feasibility of implantation, valve function and mid-to-long-term clinical outcomes of the No-ReAct Injectable BioPulmonic prosthesis for PVR in symptomatic patients. (Figure 1). The No-ReAct Injectable BioPulmonic prosthesis consists of a porcine pulmonary valve covered with a bovine pericardium sleeve and mounted on a self-expandable nitinol stent. It is available in different diameters (ranging from 15 to 31 mm). It can be inserted with or without cardiopulmonary bypass (CPB) and even in a hybrid theatre setting, in either way, the valve is inserted via a right ventricle incudinal approach (Figures 2–4).

Subsequently, the valve self-expands and can be anchored by placing 3 to 4 simple stitches on the flexible ring at the level of the predicted pulmonary valve annulus.

Data were collected from the registry of injectable pulmonary valves, from 18 different centres. The results of 85 symptomatic patients with severe PR or PSS who underwent PVR between 2007 and 2019 were analysed. The underlying diagnosis was repaired tetralogy of Fallot in 70.6% of cases. Mean age at the PVR was 26.7 ± 16.6 years. All the patients underwent echocardiography before surgery, after implantation and during follow-up.

Most of the patients also underwent pre/post-operative cardiac MRI or catheter investigation. More than one quarter of the population (25.9%) was operated on while off-pump. The mean follow-up was 4.9 years (1 month – 12.6 years). Over 90% of the patient had their follow up complete at 1 year, and 40% at 5 years.

There were no device-related deaths; 3.6% patients developed a PV stenosis and the prosthesis was explanted in only 1 patient due to endocarditis. Both echocardiography and cardiac MRI during follow up showed a good valve function, a significant reduction in RV size and low gradients across the pulmonary valve (Figures 5–6, Table 1).

This prosthesis is designed to be less obstructive; it has a low profile and a soft stent that reduces the stretch of the annulus and avoids the risk of coronary artery compression. The lack of a suture ring permits the implantation of relatively larger size prosthesis, avoiding right ventricular outflow tract obstruction and maintaining a laminar flow inside the valve. The implantation technique requires only minimal mobilisation of the heart and great vessels and thus reduces both the operative time and the risks associated with extensive dissection.

After choosing the insertion site, the introduction and the deployment of the prosthesis takes only a short time, therefore significantly reducing the operative period. Despite most of the RVOTs being able to be addressed, off-pump, with a trans-infundibular technique, in cases of heavy calcifications or highly irregular anatomies of the infundibulum, it is recommended to adopt the use of CPB and a conventional implantation technique.

Importantly, this device allows future percutaneous valve-in-valve procedures, if required. Results concerning durability are encouraging and mid to long-term haemodynamic performance, in our experience, are excellent. This leads us to the conclusion that the Injectable BioPulmonic valve prosthesis is a viable alternative to conventional prostheses.

References

Table 1: Echocardiographic assessment pre and post implantation.

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>PRE-IMPLANT</th>
<th>POST-IMPLANT</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>RV EDVI (mL/m2)</td>
<td>150.3 ± 37.8 (50-221)</td>
<td>108.6 ± 28.3 (65-171)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RV ESVI (mL/m2)</td>
<td>80.6 ± 26 (20.6-148)</td>
<td>57.4 ± 23 (27-108)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RV/LV diastolic volume ratio</td>
<td>2.1 ± 0.6 (0.8-4)</td>
<td>1.3 ± 0.4 (1.2-8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RV EDD (mm)</td>
<td>35.9 ± 10.2 (13-63)</td>
<td>30.5 ± 7.1 (19-52)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RV EDD L (mm)</td>
<td>48.3 ± 10.3 (34-88)</td>
<td>41.3 ± 8.8 (30-65)</td>
<td>&lt;0.0002</td>
</tr>
<tr>
<td>RV EF (%)</td>
<td>46.4 ± 9.5 (24-72)</td>
<td>49.4 ± 10.3 (34-70)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>RV Pmax (mmHg)</td>
<td>51.9 ± 23.8 (22-108)</td>
<td>38.4 ± 14.5 (10-60)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RV-Pa gradient (nmmHg)</td>
<td>43.9 ± 32.7 (10-120)</td>
<td>22.5 ± 14.6 (6-65)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Figure 1: Injectable BioPulmonic prosthesis.

Figure 2: The injectable implant procedure.

Figure 3: Pre- and post-implantation RV-PA gradient graph.

Figure 5: Intraoperative echocardiography.
AVALUS™
FOR ALL PATIENTS
WHY WAIT?

A design platform proven for long-term durability

You can have both – great hemodynamics and a valve designed to last. The Avalus™ pericardial valve has interior-mounted leaflets that leverage our proprietary AOA™ tissue treatment.